Date,Open,High,Low,Close,Volume,Dividends,Stock Splits,SMA_10,SMA_40,SMA_120,Close_10_%_D,10_40_%_D,40_120_%_D,RSI,earningsGrowth,revenueGrowth,profitMargins,grossMargins,returnOnEquity,debtToEquity,priceToBook,forwardPE,longName,sector,longBusinessSummary
2022-06-27,2.4800000190734863,2.5,2.390000104904175,2.5,24392,0.0,0.0,,,,,,,,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2022-06-28,2.5,2.5999999046325684,2.4100000858306885,2.549999952316284,15612,0.0,0.0,,,,,,,100.0,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2022-06-29,2.549999952316284,2.549999952316284,2.4800000190734863,2.4800000190734863,29393,0.0,0.0,,,,,,,39.87730061349693,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2022-06-30,2.5,2.680000066757202,2.5,2.5799999237060547,21876,0.0,0.0,,,,,,,68.76685462123069,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2022-07-01,2.609999895095825,3.0999999046325684,2.5799999237060547,2.7899999618530273,52081,0.0,0.0,,,,,,,85.03222726611989,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2022-07-04,2.799999952316284,3.4000000953674316,2.609999895095825,2.640000104904175,35804,0.0,0.0,,,,,,,60.711545778381144,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2022-07-05,2.6500000953674316,2.6500000953674316,2.4000000953674316,2.4000000953674316,52318,0.0,0.0,,,,,,,40.66875601283572,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2022-07-06,2.4000000953674316,2.609999895095825,2.4000000953674316,2.5199999809265137,38157,0.0,0.0,,,,,,,49.62377930251132,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2022-07-07,2.5199999809265137,2.5199999809265137,2.380000114440918,2.4700000286102295,24751,0.0,0.0,,,,,,,46.476127788626,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2022-07-08,2.440000057220459,2.440000057220459,2.059999942779541,2.059999942779541,260573,0.0,0.0,2.499000000953674,,,-17.567029131916804,,,29.789734361773114,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2022-07-11,2.0799999237060547,2.0799999237060547,1.9600000381469727,2.059999942779541,183653,0.0,0.0,2.4549999952316286,,,-16.089615202415487,,,29.789734361773114,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2022-07-12,2.049999952316284,2.059999942779541,1.8700000047683716,2.0,166745,0.0,0.0,2.4,,,-16.666666666666664,,,28.078748042417985,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2022-07-13,2.009999990463257,2.0799999237060547,1.940000057220459,2.009999990463257,78289,0.0,0.0,2.3529999971389772,,,-14.577135873046135,,,28.81261340319938,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2022-07-14,2.009999990463257,2.009999990463257,1.909999966621399,1.9249999523162842,39818,0.0,0.0,2.2875,,,-15.846996620053153,,,26.351307789737547,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2022-07-15,1.9500000476837158,1.9500000476837158,1.784999966621399,1.7999999523162842,176285,0.0,0.0,2.188499999046326,,,-17.751886995628823,,,23.211126737202875,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2022-07-18,1.7999999523162842,1.899999976158142,1.7450000047683716,1.809999942779541,70572,0.0,0.0,2.1054999828338623,,,-14.034673116292215,,,23.991476081737744,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2022-07-19,1.809999942779541,2.059999942779541,1.7949999570846558,2.049999952316284,93838,0.0,0.0,2.0704999685287477,,,-0.9900998079720051,,,39.80266120742195,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2022-07-20,1.940000057220459,1.940000057220459,1.8799999952316284,1.940000057220459,46649,0.0,0.0,2.012499976158142,,,-3.602480486786644,,,36.09643337947258,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2022-07-21,1.940000057220459,1.9500000476837158,1.7999999523162842,1.850000023841858,126722,0.0,0.0,1.9504999756813048,,,-5.152522588693833,,,33.35943947461985,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2022-07-22,1.8700000047683716,1.9149999618530273,1.850000023841858,1.8799999952316284,54322,0.0,0.0,1.9324999809265138,,,-2.7166875142588545,,,35.125265783609194,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2022-07-25,1.8799999952316284,1.8799999952316284,1.7699999809265137,1.8300000429153442,60073,0.0,0.0,1.909499990940094,,,-4.163390856347164,,,33.530549441743034,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2022-07-26,1.850000023841858,1.8899999856948853,1.8350000381469727,1.8899999856948853,36762,0.0,0.0,1.8984999895095824,,,-0.4477220891053513,,,37.21430225054482,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2022-07-27,1.8799999952316284,1.8799999952316284,1.7799999713897705,1.8200000524520874,62005,0.0,0.0,1.8794999957084655,,,-3.1657325561179355,,,34.79173443174808,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2022-07-28,1.784999966621399,1.840000033378601,1.784999966621399,1.8350000381469727,36843,0.0,0.0,1.8705000042915345,,,-1.8978864508480835,,,35.75683132846959,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2022-07-29,1.8350000381469727,1.850000023841858,1.784999966621399,1.840000033378601,82604,0.0,0.0,1.8745000123977662,,,-1.8404896660968537,,,36.096345101377125,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2022-08-01,1.8350000381469727,1.840000033378601,1.7999999523162842,1.8350000381469727,63258,0.0,0.0,1.8770000219345093,,,-2.237612322681267,,,35.89207084278456,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2022-08-02,1.8350000381469727,1.8350000381469727,1.809999942779541,1.809999942779541,16998,0.0,0.0,1.853000020980835,,,-2.32056544600216,,,34.830694732050745,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2022-08-03,1.840000033378601,1.8700000047683716,1.7000000476837158,1.725000023841858,329694,0.0,0.0,1.8315000176429748,,,-5.814905420431043,,,31.4278156395209,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2022-08-04,1.7350000143051147,1.7999999523162842,1.6449999809265137,1.7549999952316284,462107,0.0,0.0,1.822000014781952,,,-3.677278759975299,,,33.88300231406566,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2022-08-05,1.7549999952316284,1.774999976158142,1.684999942779541,1.7350000143051147,104967,0.0,0.0,1.8075000166893005,,,-4.011065101785175,,,33.033843226168074,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2022-08-08,1.7300000190734863,1.7300000190734863,1.6399999856948853,1.690000057220459,166643,0.0,0.0,1.793500018119812,,,-5.770836902909852,,,31.142674470940364,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2022-08-09,1.690000057220459,1.7400000095367432,1.684999942779541,1.6950000524520874,52586,0.0,0.0,1.7740000247955323,,,-4.453211456552843,,,31.611162583591152,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2022-08-10,1.7000000476837158,1.7400000095367432,1.6699999570846558,1.7300000190734863,172084,0.0,0.0,1.7650000214576722,,,-1.9830029438345387,,,34.947683961948115,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2022-08-11,1.725000023841858,1.725000023841858,1.659999966621399,1.7000000476837158,183288,0.0,0.0,1.7515000224113464,,,-2.9403353736033018,,,33.44165160494565,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2022-08-12,1.659999966621399,1.725000023841858,1.6449999809265137,1.684999942779541,197866,0.0,0.0,1.7360000133514404,,,-2.937792061040427,,,32.68324994058197,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2022-08-15,1.684999942779541,1.690000057220459,1.649999976158142,1.690000057220459,75857,0.0,0.0,1.7215000152587892,,,-1.8297971396529351,,,33.226855288754365,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2022-08-16,1.690000057220459,1.7000000476837158,1.6449999809265137,1.7000000476837158,132356,0.0,0.0,1.7105000257492065,,,-0.6138543061928103,,,34.36836117042634,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2022-08-17,1.7050000429153442,1.7050000429153442,1.6549999713897705,1.6950000524520874,48408,0.0,0.0,1.7075000286102295,,,-0.7320630131008624,,,34.05488078250323,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2022-08-18,1.6549999713897705,1.690000057220459,1.6399999856948853,1.684999942779541,58103,0.0,0.0,1.7005000233650207,,,-0.911501345045999,,,33.398733393281276,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2022-08-19,1.684999942779541,1.690000057220459,1.5700000524520874,1.6399999856948853,188282,0.0,0.0,1.691000020503998,1.9825000047683716,,-3.0159689054239167,-14.703656169646848,,30.546557321681902,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2022-08-22,1.649999976158142,1.649999976158142,1.5750000476837158,1.600000023841858,55702,0.0,0.0,1.6820000171661378,1.960000005364418,,-4.875148185933723,-14.18367282843922,,28.23813872971678,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2022-08-23,1.5950000286102295,1.600000023841858,1.5499999523162842,1.600000023841858,18956,0.0,0.0,1.6725000143051147,1.9362500071525575,,-4.334827494359031,-13.621690994093916,,28.23813872971678,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2022-08-24,1.600000023841858,1.690000057220459,1.600000023841858,1.6299999952316284,90967,0.0,0.0,1.662500011920929,1.915000006556511,,-1.954888207895323,-13.185378264808415,,32.66431021287724,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2022-08-25,1.649999976158142,1.6799999475479126,1.600000023841858,1.6799999475479126,41596,0.0,0.0,1.6605000019073486,1.8925000071525573,,1.1743418017564118,-12.258917007576361,,39.375731287542735,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2022-08-26,1.6799999475479126,1.690000057220459,1.649999976158142,1.6649999618530273,11181,0.0,0.0,1.6585000038146973,1.8643750071525573,,0.39191787900992175,-11.042574726009173,,38.147332753023065,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2022-08-29,1.6549999713897705,1.6699999570846558,1.5850000381469727,1.659999966621399,115449,0.0,0.0,1.6554999947547913,1.839875003695488,,0.271819503525531,-10.021061679210254,,37.72485709697149,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2022-08-30,1.659999966621399,1.6749999523162842,1.6150000095367432,1.6200000047683716,39061,0.0,0.0,1.6474999904632568,1.8203750014305116,,-1.669194892508166,-9.496670237253522,,34.438903009209184,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2022-08-31,1.6299999952316284,1.6449999809265137,1.5499999523162842,1.600000023841858,88451,0.0,0.0,1.637999987602234,1.797375002503395,,-2.3199001250300277,-8.867098667733918,,32.89602361062818,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2022-09-01,1.600000023841858,1.6299999952316284,1.5549999475479126,1.5800000429153442,49327,0.0,0.0,1.6274999976158142,1.775125002861023,,-2.918584010448813,-8.316316034492056,,31.38194903460817,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2022-09-02,1.5850000381469727,1.600000023841858,1.5549999475479126,1.5950000286102295,7310,0.0,0.0,1.6230000019073487,1.7635000050067902,,-1.7251985991505654,-7.9671110122225635,,33.841388790851624,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2022-09-05,1.600000023841858,1.7949999570846558,1.5950000286102295,1.6549999713897705,801707,0.0,0.0,1.6284999966621398,1.7533750057220459,,1.6272628051548303,-7.12197953389224,,42.68996082799555,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2022-09-06,1.6549999713897705,1.7000000476837158,1.6449999809265137,1.7000000476837158,60485,0.0,0.0,1.6384999990463256,1.7458750069141389,,3.753435988598461,-6.150211638437981,,48.27741681162598,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2022-09-07,1.6950000524520874,1.715000033378601,1.4950000047683716,1.5049999952316284,465700,0.0,0.0,1.6259999990463256,1.733250007033348,,-7.441574654714982,-6.187797925966426,,33.180876640151055,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2022-09-08,1.5099999904632568,1.5800000429153442,1.5099999904632568,1.5800000429153442,46212,0.0,0.0,1.6160000085830688,1.7246250092983246,,-2.2277206359231294,-6.2984706895472105,,40.843029668044124,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2022-09-09,1.5750000476837158,1.5800000429153442,1.2649999856948853,1.4550000429153442,1138014,0.0,0.0,1.5950000166893006,1.7160000115633012,,-8.777427730975864,-7.051281705048932,,33.87163905286988,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2022-09-12,1.440000057220459,1.440000057220459,1.3849999904632568,1.4249999523162842,58752,0.0,0.0,1.571500015258789,1.7063750118017196,,-9.32230744639094,-7.904182586483105,,32.44048607958776,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2022-09-13,1.4249999523162842,1.4299999475479126,1.3350000381469727,1.3450000286102295,173202,0.0,0.0,1.544000017642975,1.6887500137090683,,-12.888600178679594,-8.571428268898917,,28.93012461269889,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2022-09-14,1.315000057220459,1.440000057220459,1.315000057220459,1.3700000047683716,85196,0.0,0.0,1.5210000157356263,1.674500012397766,,-9.927679776796325,-9.166915229958022,,31.42730773851423,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2022-09-15,1.3700000047683716,1.409999966621399,1.350000023841858,1.3700000047683716,117729,0.0,0.0,1.500000011920929,1.662500011920929,,-8.666667074627341,-9.774436020138136,,31.42730773851423,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2022-09-16,1.3700000047683716,1.4049999713897705,1.340000033378601,1.3700000047683716,152619,0.0,0.0,1.4775000095367432,1.6497500121593476,,-7.275803998273902,-10.440975987455664,,31.42730773851423,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2022-09-19,1.3700000047683716,1.3700000047683716,1.1100000143051147,1.2300000190734863,712530,0.0,0.0,1.4350000143051147,1.6347500115633011,,-14.285713811013284,-12.218993475777177,,25.227462441007475,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2022-09-20,1.2300000190734863,1.2400000095367432,1.100000023841858,1.1649999618530273,531652,0.0,0.0,1.381500005722046,1.6166250109672546,,-15.671374807983735,-14.544189509014796,,22.962489222763494,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2022-09-21,1.1649999618530273,1.2050000429153442,1.1399999856948853,1.159999966621399,245920,0.0,0.0,1.347000002861023,1.6001250088214873,,-13.882704962318979,-15.819076919927289,,22.792965349034432,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2022-09-22,1.159999966621399,1.159999966621399,1.125,1.1349999904632568,271660,0.0,0.0,1.3024999976158143,1.5826250076293946,,-12.859885409532513,-17.70002424220366,,21.92152560112119,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2022-09-23,1.1549999713897705,1.1549999713897705,0.9800000190734863,1.059999942779541,858951,0.0,0.0,1.262999987602234,1.5631250053644181,,-16.07284614531804,-19.20032094248372,,19.511439912112678,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2022-09-26,1.0700000524520874,1.149999976158142,1.059999942779541,1.1299999952316284,281673,0.0,0.0,1.2334999918937684,1.5455000042915343,,-8.390757790215988,-20.187642286082585,,27.52077990521819,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2022-09-27,1.149999976158142,1.149999976158142,1.0099999904632568,1.0549999475479126,258752,0.0,0.0,1.2044999837875365,1.5266250044107437,,-12.411792299865606,-21.100468005732882,,24.686340693689388,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2022-09-28,1.6799999475479126,2.0399999618530273,1.399999976158142,2.0,10897020,0.0,0.0,1.2674999833106995,1.5335000038146973,,57.790929099345355,-17.345941952546635,,68.58698981659225,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2022-09-29,2.0799999237060547,2.2100000381469727,1.5950000286102295,1.5950000286102295,4671930,0.0,0.0,1.2899999856948852,1.5295000046491622,,23.643414441671467,-15.658713189034202,,54.046669539301355,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2022-09-30,1.600000023841858,1.7649999856948853,1.399999976158142,1.4850000143051147,1248603,0.0,0.0,1.3014999866485595,1.5232500046491624,,14.09911867376033,-14.557690288776776,,50.89097174576478,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2022-10-03,1.465000033378601,1.5549999475479126,1.3550000190734863,1.4199999570846558,678264,0.0,0.0,1.3204999804496764,1.5165000021457673,,7.53502295404019,-12.924498609875451,,49.06779532738625,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2022-10-04,1.409999966621399,1.965000033378601,1.3600000143051147,1.6799999475479126,1639999,0.0,0.0,1.371999979019165,1.516124999523163,,22.44897764130689,-9.506143658954684,,55.877011849531634,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2022-10-05,1.6950000524520874,1.840000033378601,1.4550000429153442,1.4600000381469727,945223,0.0,0.0,1.4019999861717225,1.509375,,4.136950966285251,-7.113872551769933,,49.80900094211876,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2022-10-06,1.465000033378601,1.9199999570846558,1.399999976158142,1.7400000095367432,1157687,0.0,0.0,1.462499988079071,1.5103749990463258,,18.974360596211433,-3.169743341718699,,56.3117630572782,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2022-10-07,1.7450000047683716,1.9299999475479126,1.6950000524520874,1.7200000286102295,592740,0.0,0.0,1.52849999666214,1.5112500011920929,,12.528624950361628,1.1414389053062113,,55.756088384806255,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2022-10-10,1.7300000190734863,2.140000104904175,1.725000023841858,2.059999942779541,1480881,0.0,0.0,1.6214999914169312,1.5204999983310699,,27.04285869156441,6.642551344736661,,62.52603222004283,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2022-10-11,2.119999885559082,3.8499999046325684,2.0799999237060547,3.559999942779541,6223864,0.0,0.0,1.871999990940094,1.5669999957084655,,90.17093803466075,19.463943590742204,,78.30099839287084,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2022-10-12,3.6600000858306885,4.449999809265137,3.2899999618530273,3.299999952316284,8424023,0.0,0.0,2.0019999861717226,1.6071249932050704,,64.83516359191547,24.570272669281167,,72.59645451486972,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2022-10-13,3.2300000190734863,3.299999952316284,2.7899999618530273,2.8399999141693115,3812996,0.0,0.0,2.1264999747276305,1.6359999924898148,,33.55278381948105,29.981661643612107,,63.74760664923619,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2022-10-14,2.890000104904175,3.299999952316284,2.6600000858306885,2.8399999141693115,1843465,0.0,0.0,2.2619999647140503,1.6659999907016754,,25.552606475320122,35.774308363672645,,63.74760664923619,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2022-10-17,2.9100000858306885,3.2799999713897705,2.8399999141693115,2.9600000381469727,1355458,0.0,0.0,2.415999972820282,1.6999999910593033,,22.516559248618712,42.11764620744645,,65.03696499669472,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2022-10-18,2.9600000381469727,3.25,2.9600000381469727,3.140000104904175,504298,0.0,0.0,2.5619999885559084,1.7384999930858611,,22.56050425176078,47.36842098045244,,66.93655845128794,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2022-10-19,3.2100000381469727,3.569999933242798,3.119999885559082,3.25,1103507,0.0,0.0,2.7409999847412108,1.7789999932050704,,18.569865672832027,54.07532294606635,,68.07798031909412,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2022-10-20,3.299999952316284,3.380000114440918,2.9600000381469727,3.119999885559082,600146,0.0,0.0,2.8789999723434447,1.8149999916553496,,8.370959205653222,58.622588737187066,,65.21270414807307,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2022-10-21,3.0999999046325684,3.0999999046325684,2.799999952316284,2.9600000381469727,416458,0.0,0.0,3.0029999732971193,1.8473749935626984,,-1.4318992851317023,62.55497577704978,,61.7670085302851,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2022-10-24,2.9800000190734863,2.9800000190734863,2.619999885559082,2.640000104904175,346040,0.0,0.0,3.0609999895095825,1.8718749970197677,,-13.753671546822128,63.525876160696285,,55.45587634425779,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2022-10-25,2.5999999046325684,2.640000104904175,2.440000057220459,2.5,657332,0.0,0.0,2.9549999952316286,1.8938749969005584,,-15.39763099715211,56.02930499994275,,52.908801039703604,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2022-10-26,2.450000047683716,2.569999933242798,2.240000009536743,2.4000000953674316,854477,0.0,0.0,2.865000009536743,1.9138749986886978,,-16.230363442284936,49.696297380952984,,51.10329468611151,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2022-10-27,2.4000000953674316,2.4600000381469727,2.0999999046325684,2.1600000858306885,710558,0.0,0.0,2.797000026702881,1.9283749997615813,,-22.774398812684012,45.04440407331011,,46.96131725913088,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2022-10-28,2.1600000858306885,2.1700000762939453,2.0,2.069999933242798,464395,0.0,0.0,2.7200000286102295,1.9402499973773957,,-23.897062078324534,40.18812175167165,,45.47288854419329,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2022-10-31,2.069999933242798,2.4800000190734863,2.069999933242798,2.2899999618530273,389906,0.0,0.0,2.653000020980835,1.9561249971389771,,-13.682625565664472,35.625280841516016,,49.672037611516075,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2022-11-01,2.2899999618530273,2.299999952316284,2.0,2.140000104904175,353673,0.0,0.0,2.553000020980835,1.9671249985694885,,-16.17704319164047,29.783314371857404,,47.01360795744863,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2022-11-02,2.119999885559082,2.359999895095825,2.0399999618530273,2.0899999141693115,345847,0.0,0.0,2.437000012397766,1.9817499965429306,,-14.23882217739675,22.972121440595323,,46.127395941208455,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2022-11-03,2.069999933242798,2.1700000762939453,2.0299999713897705,2.140000104904175,191448,0.0,0.0,2.339000034332275,1.9957499980926514,,-8.507906220912469,17.199049809228093,,47.19925767023009,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2022-11-04,2.119999885559082,2.119999885559082,1.9299999475479126,2.069999933242798,137853,0.0,0.0,2.250000023841858,2.011124995350838,,-8.000003941853796,11.877681846888315,,45.824639806926946,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2022-11-07,2.0299999713897705,2.0299999713897705,1.9550000429153442,1.975000023841858,149730,0.0,0.0,2.183500015735626,2.0248749971389772,,-9.548888957691355,7.833817831756342,,43.953736325940085,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2022-11-08,1.975000023841858,2.009999990463257,1.8799999952316284,1.8849999904632568,226758,0.0,0.0,2.122000014781952,2.038374996185303,,-11.168709833541085,4.102533574692998,,42.19610085896497,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2022-11-09,1.9199999570846558,2.0799999237060547,1.850000023841858,1.9199999570846558,433121,0.0,0.0,2.0740000009536743,2.0521249949932097,,-7.425267299817054,1.0659684967453475,,43.148210130276425,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2022-11-10,1.850000023841858,3.309999942779541,1.840000033378601,2.359999895095825,3448897,0.0,0.0,2.093999981880188,2.0768749922513963,,12.70295680598802,0.8245556276946503,,53.51437286665056,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2022-11-11,2.4000000953674316,2.640000104904175,2.1600000858306885,2.1700000762939453,495596,0.0,0.0,2.1039999961853026,2.0968749940395357,,3.1368859424099513,0.33979145948232936,,49.33142194524068,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2022-11-14,2.130000114440918,2.5299999713897705,2.0,2.1500000953674316,584237,0.0,0.0,2.0900000095367433,2.1198749959468843,,2.8708174907610475,-1.4092805692439814,,48.89814479223391,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2022-11-15,2.1500000953674316,2.5799999237060547,2.1500000953674316,2.5399999618530273,475721,0.0,0.0,2.1299999952316284,2.154249995946884,,19.248824767101148,-1.1256818271268854,,56.855784807105564,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2022-11-16,2.5399999618530273,2.950000047683716,2.4200000762939453,2.6700000762939453,386211,0.0,0.0,2.1880000114440916,2.191999998688698,,22.029253305704103,-0.18248117002733816,,59.139865153495215,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2022-11-17,2.700000047683716,2.700000047683716,2.5299999713897705,2.5999999046325684,117739,0.0,0.0,2.233999991416931,2.228624996542931,,16.383165381459968,0.24117987020418588,,57.3783872702856,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2022-11-18,2.5799999237060547,2.690000057220459,2.509999990463257,2.5999999046325684,76960,0.0,0.0,2.286999988555908,2.2671249955892563,,13.68604799487994,0.8766606607628161,,57.3783872702856,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2022-11-21,2.5999999046325684,3.5,2.5899999141693115,2.930000066757202,514523,0.0,0.0,2.3824999928474426,2.3121249973773956,,22.980066130259054,3.04373662971821,,63.347205714815026,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2022-11-22,2.930000066757202,3.180000066757202,2.609999895095825,2.7300000190734863,559465,0.0,0.0,2.4669999957084654,2.353999999165535,,10.660722489766092,4.8003397019111045,,58.042008285043984,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2022-11-23,2.7300000190734863,2.869999885559082,2.5999999046325684,2.740000009536743,201917,0.0,0.0,2.5490000009536744,2.3724999994039537,,7.493134896493081,7.439409972352497,,58.23036838098826,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2022-11-24,2.799999952316284,3.1700000762939453,2.5999999046325684,2.799999952316284,384953,0.0,0.0,2.5930000066757204,2.4026249974966047,,7.983029121004207,7.92362559190366,,59.407844894431115,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2022-11-25,2.859999895095825,2.9800000190734863,2.7799999713897705,2.819999933242798,66016,0.0,0.0,2.6579999923706055,2.435999995470047,,6.094805919382587,9.113300382322931,,59.81449831647853,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2022-11-28,2.8299999237060547,2.940000057220459,2.180000066757202,2.240000009536743,1919340,0.0,0.0,2.6669999837875364,2.456499996781349,,-16.010497819515912,8.569101863708402,,45.56007153447416,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2022-11-29,2.259999990463257,2.5999999046325684,2.180000066757202,2.390000104904175,518011,0.0,0.0,2.651999998092651,2.474250000715256,,-9.879332329446068,7.183995041972772,,48.94851288254883,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2022-11-30,2.799999952316284,2.799999952316284,2.5,2.5299999713897705,494010,0.0,0.0,2.637999987602234,2.500999999046326,,-4.094011247916201,5.477808420957559,,51.95429676228484,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2022-12-01,2.559999942779541,2.880000114440918,2.549999952316284,2.5799999237060547,341454,0.0,0.0,2.6359999895095827,2.5219999969005586,,-2.1244334607886928,4.520221758490313,,53.01820844816868,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2022-12-02,2.6600000858306885,2.6700000762939453,2.5199999809265137,2.5199999809265137,75688,0.0,0.0,2.627999997138977,2.5419999957084656,,-4.109589662482487,3.383162925873374,,51.54322039181858,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2022-12-05,2.5199999809265137,2.680000066757202,2.5,2.680000066757202,116494,0.0,0.0,2.6029999971389772,2.557499998807907,,2.9581279178969506,1.779081069492806,,55.12823302040961,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2022-12-06,2.6700000762939453,2.6700000762939453,2.5299999713897705,2.559999942779541,140935,0.0,0.0,2.5859999895095824,2.532499998807907,,-1.0054155775527343,2.1125366525906704,,52.01973604877781,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2022-12-07,2.5199999809265137,3.25,2.5199999809265137,3.0299999713897705,1367504,0.0,0.0,2.6149999856948853,2.525749999284744,,15.869980419315644,3.5336033429838882,,61.238587958565596,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2022-12-08,3.0299999713897705,3.0299999713897705,2.700000047683716,2.890000104904175,433693,0.0,0.0,2.624000000953674,2.5270000040531158,,10.137199079795153,3.8385435989306598,,57.683269600388996,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2022-12-09,2.819999933242798,2.880000114440918,2.7300000190734863,2.8499999046325684,120347,0.0,0.0,2.6269999980926513,2.5272500038146974,2.058583333094915,8.488766909091263,3.9469777080774984,22.766465810989537,56.67091472788825,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2022-12-12,2.8499999046325684,3.2799999713897705,2.8499999046325684,3.0899999141693115,464083,0.0,0.0,2.7119999885559083,2.530500000715256,2.063499999046326,13.938050413292274,7.1724950716993,22.63145150883258,61.08402336873067,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2022-12-13,3.299999952316284,3.8499999046325684,3.200000047683716,3.4200000762939453,815308,0.0,0.0,2.814999985694885,2.5375,2.0707500000794727,21.49201043245176,10.93596002738463,22.540142455758254,66.18406861968106,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2022-12-14,3.4600000381469727,3.990000009536743,3.4600000381469727,3.8399999141693115,1039777,0.0,0.0,2.9459999799728394,2.552249997854233,2.0820833325386046,30.346230151865594,15.427563226550934,22.581548873088188,71.33331048009478,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2022-12-15,3.859999895095825,4.0,3.630000114440918,3.890000104904175,839854,0.0,0.0,3.0769999980926515,2.57150000333786,2.093000000715256,26.421842941679557,19.65778705419568,22.861920805498475,71.88223168426757,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2022-12-16,3.8499999046325684,3.8499999046325684,3.069999933242798,3.140000104904175,1039789,0.0,0.0,3.1390000104904177,2.57600000500679,2.095916668574015,0.0318602870473039,21.855590232506366,22.90565000179163,54.90046788128526,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2022-12-19,3.1600000858306885,3.7300000190734863,2.9600000381469727,3.569999933242798,832667,0.0,0.0,3.2279999971389772,2.599250000715256,2.103666667143504,10.594793568988232,24.189669952898075,23.558073211507757,60.641517400642364,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2022-12-20,3.5899999141693115,3.680000066757202,3.2100000381469727,3.25,441524,0.0,0.0,3.297000002861023,2.6180000007152557,2.1107499996821084,-1.4255384537530524,25.935828951881586,24.031742324270624,55.027598842406334,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2022-12-21,3.309999942779541,3.430000066757202,3.2799999713897705,3.319999933242798,230344,0.0,0.0,3.3259999990463256,2.64099999666214,2.117416665951411,-0.18039885163103309,25.937145143882294,24.727458658944162,55.98745239669605,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2022-12-22,3.319999933242798,3.4200000762939453,3.009999990463257,3.0999999046325684,565555,0.0,0.0,3.346999979019165,2.664499992132187,2.1226666649182637,-7.379745322226738,25.61456141498533,25.526067571932547,52.215484333108286,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2022-12-23,3.0899999141693115,3.2100000381469727,2.930000066757202,3.049999952316284,227684,0.0,0.0,3.3669999837875366,2.6889999926090242,2.1309166649977365,-9.414910394940343,25.213833880329517,26.189824162451732,51.36844177933374,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2022-12-27,3.049999952316284,3.049999952316284,2.890000104904175,2.930000066757202,178738,0.0,0.0,3.3509999990463255,2.7049999952316286,2.138166666030884,-12.563411889255072,23.881700737651204,26.51025002896371,49.30134591115974,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2022-12-28,2.9200000762939453,2.9200000762939453,2.6500000953674316,2.7799999713897705,417152,0.0,0.0,3.286999988555908,2.7209999918937684,2.144666665792465,-15.424399724104653,20.80117597752044,26.872862589503864,46.76792298454124,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2022-12-29,2.7899999618530273,2.990000009536743,2.759999990463257,2.869999885559082,215269,0.0,0.0,3.189999985694885,2.7404999911785124,2.1518333315849305,-10.031351146420043,16.402116254817855,27.35651739161416,48.47861448629688,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2022-12-30,2.809999942779541,2.809999942779541,2.7300000190734863,2.7699999809265137,139306,0.0,0.0,3.077999973297119,2.756249988079071,2.1588749984900155,-10.006497564737767,11.673468901936836,27.670661340136792,46.68345336041043,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2023-01-02,2.7699999809265137,2.890000104904175,2.7699999809265137,2.8499999046325684,69324,0.0,0.0,3.0489999532699583,2.7757499873638154,2.167624998092651,-6.526731770657082,9.844185072505534,28.054898324491965,48.3318098982405,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2023-01-03,2.950000047683716,3.6500000953674316,2.950000047683716,3.3299999237060547,882816,0.0,0.0,3.0249999523162843,2.8096249848604202,2.1802916646003725,10.08264384124131,7.6656126214852724,28.86463909751262,56.9348421588399,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2023-01-04,3.369999885559082,3.6500000953674316,3.369999885559082,3.5,563886,0.0,0.0,3.049999952316284,2.849999985098839,2.19237499833107,14.754100154721936,7.01754274607511,29.9960083137411,59.50646090542261,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2023-01-05,3.509999990463257,3.640000104904175,3.4000000953674316,3.5799999237060547,162533,0.0,0.0,3.07599995136261,2.8914999842643736,2.2060416638851166,16.384914834611173,6.380770122852862,31.07186648379427,60.69590352727261,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2023-01-09,3.8499999046325684,4.699999809265137,3.8299999237060547,4.199999809265137,1658583,0.0,0.0,3.185999941825867,2.9374999821186067,2.2256249954303104,31.826738416641525,8.45957314791318,31.985396827854185,68.43442777821328,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2023-01-10,4.199999809265137,4.199999809265137,3.9100000858306885,3.9800000190734863,382850,0.0,0.0,3.278999948501587,2.9827499806880953,2.243124995628993,21.378471533439253,9.932108615592018,32.97297237114977,63.645858033403975,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2023-01-11,4.03000020980835,4.179999828338623,3.740000009536743,3.869999885559082,651544,0.0,0.0,3.372999930381775,3.0257499754428863,2.2601249943176906,14.734656550113062,11.476492035270057,33.875338003433306,61.334887647995565,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2023-01-12,3.880000114440918,3.930000066757202,3.700000047683716,3.7699999809265137,287775,0.0,0.0,3.471999931335449,3.0564999759197233,2.2757916609446207,8.582950906811906,13.593978690960032,34.304911489615506,59.2294003438413,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2023-01-13,3.7699999809265137,3.7699999809265137,3.5999999046325684,3.6500000953674316,222377,0.0,0.0,3.549999952316284,3.0809999763965608,2.291041661302249,2.8169054758972583,15.222329747248192,34.480312097218366,56.71347782347125,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2023-01-16,3.6500000953674316,3.700000047683716,3.359999895095825,3.700000047683716,318885,0.0,0.0,3.6429999589920046,3.1084999799728394,2.3065833280483883,1.5646469759358115,17.19478791902181,34.76642886355018,57.523106927869044,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2023-01-17,3.700000047683716,3.799999952316284,3.609999895095825,3.7300000190734863,115039,0.0,0.0,3.730999970436096,3.1367499828338623,2.322333327929179,-0.026801162437235175,18.944767381981944,35.06889580019495,58.03033681500829,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2023-01-18,3.7100000381469727,3.7799999713897705,3.549999952316284,3.6700000762939453,166837,0.0,0.0,3.7649999856948853,3.155249983072281,2.337624994913737,-2.5232379750834535,19.32493481955075,34.976738781350846,56.57523579956857,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2023-01-19,3.5899999141693115,3.6600000858306885,3.509999990463257,3.549999952316284,98080,0.0,0.0,3.7699999809265137,3.1757499814033507,2.35212499499321,-5.835544554993934,18.712115342926534,35.01620824417617,53.676315398962174,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2023-01-20,3.5399999618530273,3.549999952316284,3.440000057220459,3.5299999713897705,79674,0.0,0.0,3.7649999856948853,3.1954999804496764,2.3671666612227757,-6.241700270863138,17.821937372225168,34.992606680216575,53.18715727926482,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2023-01-23,3.5399999618530273,3.630000114440918,3.4600000381469727,3.509999990463257,122473,0.0,0.0,3.696000003814697,3.213249981403351,2.381791661183039,-5.0324678885137155,15.02373065292949,34.908944126847985,52.67024530206276,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2023-01-24,3.509999990463257,3.5399999618530273,3.4700000286102295,3.509999990463257,50110,0.0,0.0,3.6490000009536745,3.2304999828338623,2.3965833276510238,-3.809263098221148,12.954651612556123,34.796063444211214,52.67024530206276,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2023-01-25,3.509999990463257,3.5399999618530273,3.4200000762939453,3.4800000190734863,115000,0.0,0.0,3.6100000143051147,3.261499983072281,2.411499993999799,-3.601107886883263,10.685268528027162,35.2477707313879,51.79454705273401,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2023-01-26,3.490000009536743,3.640000104904175,3.490000009536743,3.630000114440918,107955,0.0,0.0,3.5960000276565554,3.2924999833106994,2.4276249945163726,0.9454974005247665,9.217920907646546,35.626383430222745,55.75553454446342,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2023-01-27,3.690000057220459,3.819999933242798,3.569999933242798,3.630000114440918,101357,0.0,0.0,3.5940000295639036,3.319999986886978,2.4434583286444345,1.00167180247304,8.253013366239308,35.87299394333545,55.75553454446342,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2023-01-30,3.630000114440918,3.799999952316284,3.630000114440918,3.7699999809265137,141564,0.0,0.0,3.6010000228881838,3.3497499883174897,2.4607083280881246,4.693139599115676,7.500560801461238,36.12950182194557,59.36935424323326,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2023-01-31,3.7799999713897705,3.9600000381469727,3.7799999713897705,3.9000000953674316,188802,0.0,0.0,3.618000030517578,3.3842499911785127,2.4791666626930238,7.794363252382603,6.906996821994986,36.50756288818161,62.43741396351219,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2023-02-01,3.9700000286102295,4.349999904632568,3.940000057220459,4.110000133514404,327816,0.0,0.0,3.662000036239624,3.4199999928474427,2.499333329995473,12.23375458332369,7.076024675388834,36.83648962716138,66.79879696948032,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2023-02-02,4.119999885559082,4.119999885559082,3.940000057220459,4.039999961853027,246168,0.0,0.0,3.7110000371932985,3.45699999332428,2.5188333292802176,8.8655327772122,7.347412333222775,37.24607948998964,64.12599209380824,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2023-02-03,4.039999961853027,4.050000190734863,3.9700000286102295,4.0,108653,0.0,0.0,3.758000040054321,3.4812499940395356,2.53804166217645,6.439594395059685,7.9497320355799355,37.1628388107016,62.58495284928609,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2023-02-06,4.099999904632568,4.420000076293945,4.039999961853027,4.28000020980835,382792,0.0,0.0,3.8350000619888305,3.51599999666214,2.55966666440169,11.603654253625804,9.072811877972937,37.361635620784554,68.32348097889725,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2023-02-07,4.400000095367432,4.539999961853027,4.199999809265137,4.460000038146973,293191,0.0,0.0,3.930000066757202,3.55625,2.583166664838791,13.486004131981971,10.509667958023263,37.67017236659551,71.36410927030974,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2023-02-08,4.460000038146973,4.670000076293945,4.409999847412109,4.5,273637,0.0,0.0,4.0320000648498535,3.591500002145767,2.6073333313067755,11.6071410620767,12.265072043461133,37.7461009308593,72.0071596784343,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2023-02-09,4.5,4.619999885559082,4.28000020980835,4.449999809265137,229177,0.0,0.0,4.114000034332276,3.617249995470047,2.631083329518636,8.167228296763875,13.732809163986962,37.48139235604646,69.89428964176925,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2023-02-10,4.400000095367432,4.400000095367432,4.050000190734863,4.110000133514404,141463,0.0,0.0,4.162000036239624,3.624000000953674,2.6517499973376593,-1.2493969791552766,14.845475583453977,36.66446703468079,57.53201907052037,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2023-02-13,4.119999885559082,4.340000152587891,4.010000228881836,4.050000190734863,117108,0.0,0.0,4.190000057220459,3.6280000030994417,2.671499999364217,-3.3412855506848875,15.490629923949676,35.80385566022308,55.66105686626855,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2023-02-14,4.010000228881836,4.099999904632568,3.9100000858306885,3.9600000381469727,106926,0.0,0.0,4.196000051498413,3.6485000014305116,2.690625,-5.624404443635881,15.006168284315107,35.60046462924086,52.882954757070884,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2023-02-15,3.950000047683716,3.950000047683716,3.75,3.809999942779541,156653,0.0,0.0,4.166000032424927,3.65450000166893,2.7085416664679847,-8.545369344084405,13.996443577025758,34.92500584030157,48.53500233077905,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2023-02-16,3.890000104904175,3.990000009536743,3.700000047683716,3.809999942779541,170321,0.0,0.0,4.1430000305175785,3.6685000002384185,2.726791665951411,-8.037655932540176,12.934442694516065,34.5353972599309,48.53500233077906,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2023-02-17,3.809999942779541,3.940000057220459,3.700000047683716,3.8399999141693115,121768,0.0,0.0,4.127000021934509,3.6814999997615816,2.74545833170414,-6.95420659655504,12.101046372450867,34.094185923281856,49.498111160737665,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2023-02-20,3.9700000286102295,3.990000009536743,3.799999952316284,3.9200000762939453,205927,0.0,0.0,4.091000008583069,3.702000004053116,2.7649583319822946,-4.179905449287685,10.507833714318151,33.889902109267005,52.07378714905582,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2023-02-21,3.859999895095825,3.9700000286102295,3.8499999046325684,3.930000066757202,94968,0.0,0.0,4.038000011444092,3.724000006914139,2.7844166656335196,-2.6745900044776487,8.431793876126944,33.7443512990482,52.40058457631516,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2023-02-22,3.9700000286102295,3.9700000286102295,3.740000009536743,3.759999990463257,111183,0.0,0.0,3.9640000104904174,3.7447500050067903,2.8019583324591317,-5.146317343271705,5.85486361413943,33.647597882735816,46.585089829791706,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2023-02-23,3.759999990463257,3.859999895095825,3.309999942779541,3.640000104904175,194750,0.0,0.0,3.883000040054321,3.76625000834465,2.818124999602636,-6.258046166457082,3.099901266538204,33.64382377913339,42.96067398083844,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2023-02-24,3.640000104904175,3.640000104904175,3.4600000381469727,3.5299999713897705,80358,0.0,0.0,3.825000023841858,3.7827500104904175,2.8349999994039536,-7.712419623877212,1.1169126491116705,33.43033549508727,39.896437589706366,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2023-02-27,3.5299999713897705,3.5299999713897705,3.2100000381469727,3.5,214581,0.0,0.0,3.7700000047683715,3.801000010967255,2.8509999990463255,-7.161803830951461,-0.8155750094563834,33.32164195856574,39.07779646445878,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2023-02-28,3.5,3.819999933242798,3.430000066757202,3.819999933242798,128283,0.0,0.0,3.7559999942779543,3.8252500116825106,2.870708331465721,1.7039387396790129,-1.8103396429792342,33.25108544654626,50.698519080535625,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2023-03-01,3.819999933242798,3.950000047683716,3.700000047683716,3.799999952316284,120535,0.0,0.0,3.7549999952316284,3.837000012397766,2.890499998132388,1.1984009891291605,-2.1370867057906353,32.745200307107126,50.05586556986048,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2023-03-02,3.799999952316284,3.950000047683716,3.740000009536743,3.75,78656,0.0,0.0,3.749000000953674,3.843250012397766,2.9105416645606357,0.026673754229700735,-2.4523518152619586,32.04586827235571,48.40395272246823,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2023-03-03,3.8299999237060547,3.930000066757202,3.7699999809265137,3.819999933242798,175217,0.0,0.0,3.747000002861023,3.8492500126361846,2.930958330631256,1.9482233874042132,-2.6563618741183075,31.33076551815567,50.849482573887734,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2023-03-06,3.9000000953674316,3.9000000953674316,3.680000066757202,3.680000066757202,103588,0.0,0.0,3.723000001907349,3.8362500190734865,2.9502083311478295,-1.1549807984989833,-2.9521020945733176,30.03319048932816,46.13925595746423,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2023-03-07,3.6600000858306885,3.7300000190734863,3.5299999713897705,3.569999933242798,84372,0.0,0.0,3.6869999885559084,3.8260000169277193,2.9685416638851168,-3.17331314554563,-3.6330378399587158,28.884834714443354,42.785709862621125,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2023-03-08,3.569999933242798,3.7100000381469727,3.569999933242798,3.6500000953674316,71599,0.0,0.0,3.6759999990463257,3.820500022172928,2.988708331187566,-0.7072879131022651,-3.7822280405175124,27.831143049507563,45.86730567402199,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2023-03-09,3.6500000953674316,3.700000047683716,3.609999895095825,3.6500000953674316,48374,0.0,0.0,3.6769999980926515,3.817500025033951,3.0094166656335193,-0.734291616514153,-3.6804198040588023,26.85182708757014,45.867305674021985,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2023-03-10,3.6500000953674316,3.6500000953674316,3.380000114440918,3.5399999618530273,112540,0.0,0.0,3.677999997138977,3.814750021696091,3.029249998927116,-3.752040114010233,-3.584770267497446,25.93051161334254,42.23936440682785,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2023-03-13,3.5399999618530273,3.569999933242798,3.0999999046325684,3.200000047683716,367868,0.0,0.0,3.6480000019073486,3.8022500216960906,3.046458332737287,-12.280700493130402,-4.05680896596944,24.808863487054946,33.43611338552172,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2023-03-14,3.180000066757202,3.390000104904175,3.1500000953674316,3.2200000286102295,107594,0.0,0.0,3.588000011444092,3.789500021934509,3.0644583334525426,-10.256409745265037,-5.317324431299332,23.6597013105773,34.3034816400738,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2023-03-15,3.299999952316284,3.440000057220459,2.9800000190734863,2.9800000190734863,301348,0.0,0.0,3.506000018119812,3.7722500205039977,3.0798750003178914,-15.002852148540708,-7.0581218354294775,22.48062080813807,29.359470598626146,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2023-03-16,3.0199999809265137,3.2699999809265137,3.0199999809265137,3.0999999046325684,174605,0.0,0.0,3.4410000085830688,3.761000019311905,3.0969166666269303,-9.909912906129781,-8.508375673642831,21.443371720049367,34.446794837560915,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2023-03-17,3.0999999046325684,3.119999885559082,2.950000047683716,3.0199999809265137,131007,0.0,0.0,3.3610000133514406,3.7482500195503237,3.1054166664679843,-10.14579086790591,-10.331488139239477,20.700389742336263,32.75329969173505,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2023-03-20,3.049999952316284,3.069999933242798,2.759999990463257,2.940000057220459,141565,0.0,0.0,3.2870000123977663,3.7340000212192535,3.1166250000397366,-10.55673726402518,-11.971076761684897,19.809089036109427,31.106391265924202,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2023-03-21,2.9800000190734863,2.9800000190734863,2.7699999809265137,2.8499999046325684,186078,0.0,0.0,3.2150000095367433,3.717500019073486,3.1279999991257985,-11.353035888692535,-13.517148808568969,18.84590857136953,29.32023211524519,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2023-03-22,2.859999895095825,3.0899999141693115,2.809999942779541,2.930000066757202,137403,0.0,0.0,3.14300000667572,3.7037500202655793,3.14058333337307,-6.776962757432611,-15.14006103332131,17.931913504987413,33.00287007672209,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2023-03-23,2.950000047683716,3.119999885559082,2.819999933242798,2.9800000190734863,258491,0.0,0.0,3.0759999990463256,3.6875000178813933,3.1514166673024495,-3.120935630773824,-16.583051277824733,17.01086867189227,35.27280852385101,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2023-03-24,2.9800000190734863,3.0,2.890000104904175,2.9600000381469727,83608,0.0,0.0,3.01800000667572,3.6707500159740447,3.1639166673024497,-1.9218014711879876,-17.782469698501526,16.019175027884675,34.76540917878086,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2023-03-27,2.9600000381469727,3.0,2.8399999141693115,2.859999895095825,80477,0.0,0.0,2.983999991416931,3.6480000138282778,3.1732499996821084,-4.1554992184241035,-18.201754931314625,14.961002574449827,32.266142323349456,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2023-03-28,2.859999895095825,2.9100000858306885,2.7100000381469727,2.740000009536743,108417,0.0,0.0,2.9359999895095825,3.6190000116825103,3.181749999523163,-6.6757486605297425,-18.872617296715454,13.742437722161593,29.52333330943418,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2023-03-29,2.859999895095825,3.25,2.7799999713897705,3.1600000858306885,435236,0.0,0.0,2.9539999961853027,3.5952500104904175,3.1909166673819223,6.9735981689711375,-17.83603400136403,12.671385224241597,46.62503560618278,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2023-03-30,3.1600000858306885,3.3499999046325684,3.0799999237060547,3.140000104904175,168671,0.0,0.0,2.9580000162124636,3.5727500140666963,3.187416668732961,6.152808914610864,-17.2066334177826,12.089205315190577,46.05196641406569,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2023-03-31,3.140000104904175,3.259999990463257,3.140000104904175,3.1600000858306885,71003,0.0,0.0,2.9720000267028808,3.5517500162124636,3.1862500031789143,6.325708527545803,-16.322939026204892,11.471165560420268,46.75672012192924,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2023-04-03,3.190000057220459,3.244999885559082,3.055000066757202,3.0999999046325684,105875,0.0,0.0,2.988000011444092,3.522250008583069,3.188416669766108,3.748323050853913,-15.16786133400835,10.47019174070025,44.86324293335874,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2023-04-04,3.134999990463257,3.200000047683716,3.0199999809265137,3.0950000286102295,88227,0.0,0.0,3.012500023841858,3.4881250083446504,3.1905416707197825,2.7385893482304033,-13.635548707828807,9.327047515343486,44.700791849913635,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2023-04-05,3.130000114440918,3.8299999237060547,3.1050000190734863,3.2899999618530273,383138,0.0,0.0,3.0485000133514406,3.457875007390976,3.1932916700839997,7.921927093452365,-11.838918213195203,8.28559883162869,52.0008366699097,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2023-04-06,3.2899999618530273,3.2899999618530273,2.75,2.880000114440918,376463,0.0,0.0,3.0385000228881838,3.4186250150203703,3.191125003496806,-5.216386613570171,-11.119236256156672,7.129147597611247,40.0342089295431,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2023-04-11,2.880000114440918,2.884999990463257,2.690000057220459,2.690000057220459,157371,0.0,0.0,3.011500024795532,3.383125013113022,3.186458337306976,-10.675741820619828,-10.984666155612581,6.171951897298552,35.91007737075019,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2023-04-12,2.690000057220459,2.7249999046325684,2.555000066757202,2.6649999618530273,245016,0.0,0.0,2.9920000314712523,3.348500007390976,3.1826666712760927,-10.929146596881203,-10.646557417734481,5.210515371010944,35.39342729707465,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2023-04-13,2.6649999618530273,2.680000066757202,2.4000000953674316,2.5250000953674316,164180,0.0,0.0,2.970500040054321,3.3126250088214872,3.1790416717529295,-14.997473108222636,-10.327911183912782,4.202000189412416,32.56765428185281,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2023-04-14,2.5250000953674316,2.950000047683716,2.5250000953674316,2.759999990463257,209219,0.0,0.0,2.930500030517578,3.2863750100135802,3.1800416707992554,-5.818121081002274,-10.828800073383334,3.3437718816936,41.072345320441606,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2023-04-17,2.755000114440918,2.869999885559082,2.5,2.555000066757202,182907,0.0,0.0,2.8720000267028807,3.2550000131130217,3.180500004688899,-11.037602959551553,-11.766512591926134,2.3423992552834463,36.721430518022906,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2023-04-18,2.5950000286102295,2.9000000953674316,2.5950000286102295,2.6449999809265137,153197,0.0,0.0,2.8205000162124634,3.225125014781952,3.182541670401891,-6.222302225745834,-12.546025245996391,1.338029436537858,39.739550645023236,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2023-04-19,2.6449999809265137,2.6600000858306885,2.509999990463257,2.5999999046325684,175051,0.0,0.0,2.7705000162124636,3.1921250104904173,3.1862083355585735,-6.154127795782691,-13.20828579370637,0.18569642373390277,38.74449869948112,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2023-04-20,2.555000066757202,2.630000114440918,2.5,2.625,69750,0.0,0.0,2.7235000133514404,3.1595000088214875,3.1908333361148835,-3.6166701989558603,-13.799651661741178,-0.9819794389996891,39.64861262414853,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2023-04-21,2.549999952316284,2.9000000953674316,2.4800000190734863,2.7899999618530273,324672,0.0,0.0,2.6735000133514406,3.135250008106232,3.19500000278155,4.357581743773585,-14.727692961037564,-1.8701093778810685,45.3787681771547,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2023-04-24,2.825000047683716,2.825000047683716,2.5999999046325684,2.6600000858306885,117304,0.0,0.0,2.6515000104904174,3.1107500076293944,3.1993333359559375,0.3205761005710471,-14.76332061440569,-2.768805842485778,41.995577402389436,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2023-04-25,2.6649999618530273,2.6649999618530273,2.434999942779541,2.5399999618530273,170816,0.0,0.0,2.6365000009536743,3.086000007390976,3.203083336353302,-3.660156990925128,-14.565781119920556,-3.6553319619721414,39.09789613126352,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2023-04-26,2.559999942779541,2.559999942779541,2.365000009536743,2.4100000858306885,211170,0.0,0.0,2.6110000133514406,3.0587500095367433,3.2053333361943563,-7.698197108116887,-14.638332481872741,-4.573107108780432,36.18502134145999,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2023-04-27,2.4100000858306885,2.7100000381469727,2.4100000858306885,2.549999952316284,181293,0.0,0.0,2.6134999990463257,3.0270000100135803,3.209333336353302,-2.4296937728415102,-13.660390142033712,-5.681345850690078,41.260403556901274,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2023-04-28,2.549999952316284,2.6449999809265137,2.4649999141693115,2.5299999713897705,82311,0.0,0.0,2.590499997138977,2.9952500104904174,3.2139583359162014,-2.3354574721491805,-13.513062747145103,-6.804952104752066,40.7616516811043,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2023-05-02,2.5199999809265137,2.5199999809265137,2.4649999141693115,2.490000009536743,120766,0.0,0.0,2.583999991416931,2.963750010728836,3.2190000027418137,-3.637770208684996,-12.8131596098592,-7.929480950468033,39.72733116214866,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2023-05-03,2.490000009536743,2.7950000762939453,2.490000009536743,2.7100000381469727,150442,0.0,0.0,2.590499997138977,2.9360000133514403,3.2255833367506663,4.613010659717232,-11.767711670344152,-8.977703973723449,47.6025300016919,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2023-05-04,2.7100000381469727,3.299999952316284,2.5999999046325684,2.9200000762939453,161981,0.0,0.0,2.622500014305115,2.917000013589859,3.2302500049273175,11.344139575444736,-10.095988958269224,-9.697391559775168,53.806923236374,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2023-05-05,3.2149999141693115,3.5850000381469727,3.049999952316284,3.4700000286102295,948990,0.0,0.0,2.7070000171661377,2.9145000159740446,3.2410833378632864,28.18618421151136,-7.119574461163937,-10.076362988695774,65.37191712835329,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2023-05-08,3.5799999237060547,3.5999999046325684,3.190000057220459,3.2899999618530273,312262,0.0,0.0,2.7570000171661375,2.9055000126361845,3.2505833367506662,19.332605780494312,-5.110996208026573,-10.616042979517406,60.0712572650934,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2023-05-09,3.194999933242798,3.2300000190734863,2.755000114440918,3.075000047683716,385626,0.0,0.0,2.7985000133514406,2.8911250114440916,3.2550416707992555,9.880294193786444,-3.203770080021052,-11.180092181916873,54.397533027468135,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2023-05-10,3.140000104904175,3.2850000858306885,3.055000066757202,3.1449999809265137,88042,0.0,0.0,2.859000015258789,2.8812500119209288,3.25900000333786,10.003496472238977,-0.772234154276179,-11.590978552624751,55.85932148889174,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2023-05-11,3.259999990463257,3.2850000858306885,3.069999933242798,3.109999895095825,33957,0.0,0.0,2.928999996185303,2.8790000081062317,3.263250003258387,6.179580032306406,1.7367137178981973,-11.775070704618955,54.911523351393654,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2023-05-12,3.109999895095825,3.109999895095825,2.924999952316284,3.015000104904175,58718,0.0,0.0,2.9755000114440917,2.87387501001358,3.2667083382606505,1.3275111177335408,3.536166363408802,-12.02535664559002,52.316751462784254,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2023-05-15,3.015000104904175,3.0399999618530273,2.799999952316284,2.9149999618530273,403703,0.0,0.0,3.0140000104904177,2.8722500085830687,3.2665833373864492,-3.2846731351298737,4.935155417660761,-12.071736370236968,49.65678042132854,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2023-05-16,2.9149999618530273,2.9749999046325684,2.809999942779541,2.9100000858306885,50812,0.0,0.0,3.056000018119812,2.867500013113022,3.2680833379427594,-4.777484666997782,6.573670589181625,-12.257439098291249,49.521208213372404,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2023-05-17,2.9100000858306885,3.180000066757202,2.8350000381469727,2.950000047683716,74734,0.0,0.0,3.0800000190734864,2.865750014781952,3.269833338260651,-4.220778265737696,7.476227974750138,-12.357918024459504,50.68129061633911,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2023-05-19,2.9800000190734863,3.390000104904175,2.9800000190734863,3.174999952316284,74786,0.0,0.0,3.10550000667572,2.8716250121593476,3.2729583382606506,2.237963145746704,8.144343134151342,-12.262096996767264,56.70817940744797,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2023-05-22,3.2799999713897705,3.2799999713897705,3.0299999713897705,3.055000066757202,41845,0.0,0.0,3.0640000104904175,2.8767500162124633,3.274916672706604,-0.29373184407316044,6.509081193105824,-12.15806984686025,52.98897398410514,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2023-05-23,3.0999999046325684,3.184999942779541,3.059999942779541,3.119999885559082,41192,0.0,0.0,3.047000002861023,2.8815000116825105,3.28225000500679,2.3957952947001853,5.743536023165833,-12.209612086616495,54.72124153174663,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2023-05-24,3.055000066757202,3.069999933242798,2.944999933242798,2.9700000286102295,69366,0.0,0.0,3.0365000009536742,2.8812500119209288,3.2870833377043405,-2.190020494732721,5.38828593112058,-12.346304735517927,50.130521145661135,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2023-05-25,3.384999990463257,3.384999990463257,2.8450000286102295,3.0350000858306885,38523,0.0,0.0,3.025500011444092,2.883125013113022,3.291291671991348,0.3140001437997698,4.938217998994856,-12.401412562484044,52.009357857865865,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2023-05-26,3.059999942779541,3.0999999046325684,2.9100000858306885,2.9800000190734863,36244,0.0,0.0,3.012500023841858,2.886125016212463,3.2946250061194102,-1.078838324021795,4.3787087156480835,-12.398982862941986,50.28308176553622,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2023-05-29,3.0999999046325684,3.0999999046325684,2.9000000953674316,3.0,119704,0.0,0.0,3.0110000133514405,2.892625015974045,3.298625006278356,-0.36532757564477003,4.092303590119325,-12.308158385132018,50.92101522727406,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2023-05-30,3.0,3.0999999046325684,2.9700000286102295,2.9749999046325684,65266,0.0,0.0,3.0170000076293944,2.888000011444092,3.301083338260651,-1.3921147792713313,4.466758852982084,-12.513568561835026,50.056390836648326,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2023-05-31,2.9749999046325684,2.9749999046325684,2.8550000190734863,2.9000000953674316,52160,0.0,0.0,3.016000008583069,2.8820000112056734,3.3039166728655496,-3.84615095774269,4.64954881528044,-12.770196812922036,47.45323918926391,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2023-06-01,2.8399999141693115,3.1549999713897705,2.6649999618530273,2.9749999046325684,150668,0.0,0.0,3.018499994277954,2.87737500667572,3.3034583389759065,-1.4411161082606254,4.904643547497755,-12.898099160901626,50.24003218325313,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2023-06-02,2.9749999046325684,2.9749999046325684,2.7049999237060547,2.755000114440918,62707,0.0,0.0,2.9765000104904176,2.868750011920929,3.3023333390553793,-7.441622552287665,3.755991219929916,-13.129605119102703,43.030857453544215,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2023-06-05,2.7950000762939453,2.7950000762939453,2.559999942779541,2.619999885559082,81945,0.0,0.0,2.9329999923706054,2.8568750083446504,3.3004166722297668,-10.671670904388245,2.664624241648705,-13.438959620376023,39.30379202088151,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2023-06-07,2.684999942779541,2.8450000286102295,2.5299999713897705,2.700000047683716,193920,0.0,0.0,2.891000008583069,2.8421250104904177,3.297166673342387,-6.6067091086923115,1.7196639103576143,-13.800990605994656,42.48303710565338,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2023-06-08,2.744999885559082,2.8550000190734863,2.700000047683716,2.7799999713897705,61916,0.0,0.0,2.872000002861023,2.839625006914139,3.291833339134852,-3.2033437109889955,1.1401151866198822,-13.73727906709764,45.55424933457151,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2023-06-09,2.8299999237060547,2.9000000953674316,2.7300000190734863,2.9000000953674316,54458,0.0,0.0,2.8585000038146973,2.844875007867813,3.284000007311503,1.4518135909516208,0.47893126795387275,-13.371650379598703,49.87761909538688,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2023-06-12,3.0,3.319999933242798,2.9000000953674316,3.1050000190734863,89328,0.0,0.0,2.8710000038146974,2.8558750092983245,3.2774583399295807,8.15047074008614,0.5296098207074227,-12.863117907406089,56.266558038600074,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2023-06-13,3.140000104904175,3.140000104904175,2.7699999809265137,3.0,114176,0.0,0.0,2.8710000038146974,2.8677500069141386,3.2762916723887128,4.4932078026436875,0.1133291567508706,-12.469636599134361,52.570335143656756,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2023-06-14,3.0,3.0450000762939453,2.825000047683716,2.9700000286102295,14058,0.0,0.0,2.870500016212463,2.8730000078678133,3.271291673183441,3.466295482870385,-0.08701676465380334,-12.175363896183319,51.52879988293126,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2023-06-15,3.055000066757202,3.109999895095825,2.9000000953674316,3.005000114440918,81167,0.0,0.0,2.881000018119812,2.884250009059906,3.2692500074704487,4.304064406151249,-0.1126806251151966,-11.776401239758133,52.7060580125722,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2023-06-16,3.005000114440918,3.0850000381469727,2.950000047683716,3.0199999809265137,58148,0.0,0.0,2.8855000257492067,2.893625009059906,3.266750007867813,4.661235625613438,-0.2807890893000952,-11.421902438486367,53.23032826311494,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2023-06-19,3.0199999809265137,3.075000047683716,2.9749999046325684,2.9800000190734863,18193,0.0,0.0,2.9080000162124633,2.903125011920929,3.2657500088214872,2.4759285577583916,0.16792264444405544,-11.103881066249128,51.58801725524698,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2023-06-20,2.9749999046325684,3.0450000762939453,2.9649999141693115,3.0350000858306885,92892,0.0,0.0,2.949500036239624,2.913375014066696,3.2656250099341073,2.898798051891872,1.23997157930253,-10.786602711452128,53.70314253199098,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2023-06-21,3.0350000858306885,3.0450000762939453,2.9700000286102295,3.0,29604,0.0,0.0,2.9795000314712525,2.9186250150203703,3.266208342711131,0.6880338416584864,2.0857429830004164,-10.641799028724769,52.14193392622088,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2023-06-22,3.0,3.0399999618530273,2.994999885559082,3.0,90030,0.0,0.0,3.0015000343322753,2.9271250128746034,3.268041676282883,-0.049976155759365336,2.54088981955135,-10.431833409053795,52.141933926220865,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2023-06-26,3.109999895095825,3.134999990463257,3.0199999809265137,3.0999999046325684,94559,0.0,0.0,3.021500015258789,2.941125011444092,3.269958343108495,2.598043653064683,2.7327979430304112,-10.056193295471976,56.34702076385752,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2023-06-27,3.140000104904175,3.194999933242798,3.109999895095825,3.140000104904175,64308,0.0,0.0,3.0250000238418577,2.9593750119209288,3.2730416774749758,3.801655542344852,2.217529432957258,-9.583338571967975,57.939032783518,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2023-06-28,3.140000104904175,3.1649999618530273,3.0399999618530273,3.055000066757202,111225,0.0,0.0,3.030500030517578,2.972000014781952,3.2747500121593474,0.8084486386043553,1.9683719866979248,-9.244980418452279,53.47597221535773,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2023-06-29,3.055000066757202,3.055000066757202,3.0,3.049999952316284,36429,0.0,0.0,3.0385000228881838,2.9850000143051147,3.272416679064433,0.37847389637895695,1.7922950863209097,-8.783009407026036,53.216284386564645,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2023-06-30,3.005000114440918,3.0850000381469727,3.0,3.069999933242798,40754,0.0,0.0,3.0450000047683714,2.999500012397766,3.2688333451747895,0.8210157121601762,1.516919225955696,-8.239432982247116,54.17487005555522,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2023-07-03,3.1500000953674316,3.194999933242798,3.069999933242798,3.0999999046325684,124063,0.0,0.0,3.052999997138977,3.009250009059906,3.2648333450158438,1.5394663458118534,1.453850226712755,-7.828373118833652,55.64303217388359,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2023-07-04,2.994999885559082,3.180000066757202,2.994999885559082,3.1500000953674316,35393,0.0,0.0,3.0700000047683718,3.015000009536743,3.2560833474000295,2.605866139244381,1.8242121080483669,-7.404089887803105,58.05507615849302,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2023-07-05,3.1500000953674316,3.1600000858306885,3.075000047683716,3.1500000953674316,25903,0.0,0.0,3.081500005722046,3.0070000112056734,3.2491666813691458,2.2229462767544232,2.4775521861904313,-7.453193200338595,58.05507615849302,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2023-07-06,3.1500000953674316,3.1500000953674316,2.9649999141693115,3.065000057220459,87896,0.0,0.0,3.088000011444092,3.001375013589859,3.242458349466324,-0.7448171676941524,2.8861770842365804,-7.435202241414911,52.43360582001646,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2023-07-07,3.1700000762939453,3.3499999046325684,3.0999999046325684,3.194999933242798,209189,0.0,0.0,3.1075000047683714,3.004375010728836,3.237666682402293,2.8157659964653345,3.4324940685256897,-7.205549383494857,58.976253640442316,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2023-07-10,3.194999933242798,3.5999999046325684,3.125,3.315000057220459,174329,0.0,0.0,3.129000020027161,3.008625012636185,3.234875015417735,5.944392329907483,4.0009973620973875,-6.9940879231259325,63.91086771599354,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2023-07-11,3.380000114440918,3.5199999809265137,3.319999933242798,3.3399999141693115,60931,0.0,0.0,3.1490000009536745,3.014375013113022,3.231875014305115,6.0654148351156785,4.466099514991063,-6.729839496557931,64.8592201905932,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2023-07-12,3.4000000953674316,3.569999933242798,3.380000114440918,3.490000009536743,61330,0.0,0.0,3.1924999952316284,3.026250010728836,3.229875014225642,9.318716202019289,5.49359715533724,-6.304423626300118,69.95995370089253,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2023-07-13,3.5250000953674316,3.575000047683716,3.299999952316284,3.4200000762939453,87807,0.0,0.0,3.2295000076293947,3.038875013589859,3.2277916808923086,5.8987480481347525,6.2728803648409395,-5.852814740826906,65.20350358950895,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2023-07-14,3.450000047683716,3.450000047683716,2.9000000953674316,3.2950000762939453,162250,0.0,0.0,3.252000021934509,3.0485000133514406,3.2256666819254556,1.3222648852830228,6.675414390415106,-5.492404704017997,57.6641149045929,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2023-07-17,3.4149999618530273,3.5,3.2950000762939453,3.4200000762939453,81921,0.0,0.0,3.284000039100647,3.060250014066696,3.2247500161329907,4.141292191657317,7.311494943402173,-5.101170671938078,62.352142413945046,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2023-07-18,3.490000009536743,3.490000009536743,3.369999885559082,3.434999942779541,18552,0.0,0.0,3.312500023841858,3.0667500138282775,3.224125015735626,3.698110733765582,8.01336949231171,-4.881169344838242,62.88328738722005,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2023-07-19,3.490000009536743,3.490000009536743,3.359999895095825,3.4149999618530273,21783,0.0,0.0,3.3390000104904174,3.075750011205673,3.223333348830541,2.27612911422086,8.558888021642309,-4.578593699544382,61.63468302749464,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2023-07-20,3.4149999618530273,3.4149999618530273,3.2899999618530273,3.380000114440918,84924,0.0,0.0,3.370500016212463,3.082250016927719,3.2225000162919364,0.28186020420585334,9.351934388893667,-4.3522109745588216,59.411469596056094,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2023-07-21,3.380000114440918,3.4749999046325684,3.309999942779541,3.4149999618530273,73684,0.0,0.0,3.3925000190734864,3.093375015258789,3.220708348353704,0.6632260177756995,9.669859048424266,-3.953581613808731,60.929194427915256,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2023-07-24,3.4000000953674316,3.494999885559082,3.359999895095825,3.4649999141693115,56233,0.0,0.0,3.4075000047683717,3.1041250109672545,3.2193333466847736,1.687451484093203,9.773285313228563,-3.5786395290863275,63.05458330994956,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2023-07-25,3.4649999141693115,3.4649999141693115,3.359999895095825,3.4149999618530273,66662,0.0,0.0,3.415000009536743,3.115000009536743,3.216375013192495,-1.396302064700295e-06,9.63081859009738,-3.1518402934964156,59.565088828194604,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2023-07-26,3.4200000762939453,3.4200000762939453,3.359999895095825,3.380000114440918,65428,0.0,0.0,3.4040000200271607,3.124500012397766,3.2120416800181073,-0.705050101205677,8.945431477687977,-2.7254212846904156,57.1796483726177,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2023-07-27,3.4200000762939453,3.440000057220459,3.359999895095825,3.390000104904175,83539,0.0,0.0,3.4010000228881836,3.134875017404556,3.2060416797796885,-0.32343187033169973,8.489174337290144,-2.21976722336382,57.70087463777203,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2023-07-28,3.390000104904175,3.430000066757202,3.359999895095825,3.430000066757202,99585,0.0,0.0,3.414500021934509,3.1481250166893004,3.2009583473205567,0.45394771483736296,8.461385867240425,-1.650547270491094,59.808322644987804,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2023-07-31,3.450000047683716,3.4800000190734863,3.359999895095825,3.430000066757202,99271,0.0,0.0,3.415500020980835,3.159500020742416,3.196208347876867,0.42453654478980496,8.102547825850756,-1.1484960659349601,59.808322644987804,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2023-08-01,3.430000066757202,3.430000066757202,3.359999895095825,3.369999885559082,66927,0.0,0.0,3.409000015258789,3.1748750150203704,3.1886250118414563,-1.1440343069856656,7.374306047663945,-0.4312202523038347,55.03797247498707,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2023-08-02,3.369999885559082,3.3949999809265137,3.359999895095825,3.384999990463257,35441,0.0,0.0,3.406000018119812,3.194000017642975,3.1796666781107583,-0.6165598222206604,6.637445188033632,0.45078119762959123,55.98319395217868,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2023-08-03,3.359999895095825,3.4000000953674316,3.359999895095825,3.3949999809265137,54802,0.0,0.0,3.4075000047683717,3.2113750159740446,3.1704583446184795,-0.36683855684125527,6.107196693589528,1.2905601306832133,56.63766483353051,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2023-08-04,3.3949999809265137,3.3949999809265137,3.359999895095825,3.384999990463257,33848,0.0,0.0,3.4045000076293945,3.226500016450882,3.161583346128464,-0.5727718349959956,5.516813583478937,2.0532961878709384,55.74505263850171,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2023-08-07,3.384999990463257,3.4049999713897705,3.359999895095825,3.4049999713897705,59458,0.0,0.0,3.3985000133514403,3.2391250133514404,3.155708344777425,0.19125961491229493,4.920310248695791,2.6433579868705794,57.19795579428276,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2023-08-08,3.4049999713897705,3.4049999713897705,3.359999895095825,3.4000000953674316,48335,0.0,0.0,3.397000026702881,3.246500015258789,3.1502916773160297,0.0883152381798025,4.635761920121079,3.05395016707553,56.696828632020186,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2023-08-09,3.494999885559082,3.7799999713897705,3.430000066757202,3.5,879909,0.0,0.0,3.409000015258789,3.2590000152587892,3.146458343664805,2.6694040579023794,4.602638824722091,3.5767729714451724,63.57125785041445,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2023-08-10,3.4149999618530273,3.674999952316284,3.4000000953674316,3.625,326280,0.0,0.0,3.4325000047683716,3.2753750145435334,3.1449166774749755,5.608157173028715,4.797160310717446,4.148228727423764,69.98547338963343,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2023-08-11,3.6500000953674316,3.6500000953674316,3.4700000286102295,3.549999952316284,159275,0.0,0.0,3.4444999933242797,3.2890000104904176,3.1427500108877817,3.062852640338858,4.727880277831796,4.65356770649799,62.83644250664503,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2023-08-14,3.549999952316284,3.5850000381469727,3.315000057220459,3.3499999046325684,453931,0.0,0.0,3.4364999771118163,3.297250008583069,3.1386666774749754,-2.517098008303971,4.22321535116433,5.052570005161305,48.58408926441119,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2023-08-15,3.384999990463257,3.5299999713897705,3.180000066757202,3.200000047683716,415996,0.0,0.0,3.41949999332428,3.3027500092983244,3.132666677236557,-6.419065537917322,3.534932516759243,5.429346610594534,41.061677459685605,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2023-08-16,3.200000047683716,3.424999952316284,3.0999999046325684,3.424999952316284,75871,0.0,0.0,3.4234999895095823,3.3125000059604646,3.1284583429495494,0.04381372312832132,3.35094289356637,5.882822874265873,52.853667980830814,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2023-08-17,3.200000047683716,3.3949999809265137,3.0999999046325684,3.2750000953674316,49374,0.0,0.0,3.4115000009536742,3.3193750083446503,3.1244166771570843,-4.0011697361302785,2.775371640065642,6.239831345573252,46.21520646285061,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2023-08-18,3.299999952316284,3.299999952316284,3.119999885559082,3.2950000762939453,51901,0.0,0.0,3.4025000095367433,3.326750010251999,3.1215416769186657,-3.159439616208385,2.276997040694571,6.573941807366748,47.16803012508318,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2023-08-21,3.2950000762939453,3.2950000762939453,3.125,3.1500000953674316,56631,0.0,0.0,3.377000021934509,3.3280000150203706,3.118375011285146,-6.721940334398958,1.4723559703421036,6.722251267939508,41.43663262543859,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2023-08-22,3.1600000858306885,3.3949999809265137,3.0250000953674316,3.380000114440918,358754,0.0,0.0,3.375000023841858,3.334000015258789,3.11737501223882,0.14815083151817,1.2297543010024965,6.948955520894939,51.50299038602168,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2023-08-23,3.369999885559082,3.369999885559082,3.240000009536743,3.299999952316284,43682,0.0,0.0,3.3550000190734863,3.340125012397766,3.1130416790644326,-1.6393462427577248,0.4453428126344922,7.294580566026313,48.38749482348834,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2023-08-24,3.1500000953674316,3.3949999809265137,3.1500000953674316,3.309999942779541,23042,0.0,0.0,3.3235000133514405,3.3466250121593477,3.1089583456516268,-0.4062004067298299,-0.6909946206666943,7.644575452100721,48.80438423440012,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2023-08-25,3.319999933242798,3.6549999713897705,3.2049999237060547,3.4000000953674316,101307,0.0,0.0,3.3085000276565553,3.354875016212463,3.1060416797796884,2.7656057713769107,-1.3823164300249755,8.011268427358148,52.52138229373316,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2023-08-28,3.4000000953674316,3.4000000953674316,3.240000009536743,3.3399999141693115,56763,0.0,0.0,3.3075000286102294,3.360875016450882,3.1020416796207426,0.9826117997869881,-1.5881277220780785,8.343967088855639,49.9192941785853,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2023-08-29,3.440000057220459,3.440000057220459,3.1549999713897705,3.299999952316284,107550,0.0,0.0,3.3175000190734862,3.3646250128746034,3.0988750120004016,-0.5275076610878058,-1.4006016605355787,8.575692786739838,48.20467869020099,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2023-08-30,3.299999952316284,3.3299999237060547,3.069999933242798,3.1600000858306885,86215,0.0,0.0,3.2910000324249267,3.3648750126361846,3.0954583466053007,-3.9805513613961514,-2.195474718491287,8.703611415942499,42.6792293335678,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2023-08-31,3.1600000858306885,3.1600000858306885,3.0399999618530273,3.1500000953674316,80747,0.0,0.0,3.278500032424927,3.367000013589859,3.0912916799386343,-3.9194734112127163,-2.628452058441614,8.918871533232279,42.30620332749225,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2023-09-01,3.0,3.2799999713897705,3.0,3.0999999046325684,76818,0.0,0.0,3.2590000152587892,3.3646250128746034,3.0867083450158437,-4.878800548689015,-3.1392799260435944,9.003658162505571,40.40464105114241,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2023-09-04,3.0999999046325684,3.200000047683716,3.005000114440918,3.1449999809265137,138727,0.0,0.0,3.258500003814697,3.3603750109672545,3.0834166785081227,-3.483198488731319,-3.031655896144566,8.982189607702812,42.89250092031184,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2023-09-05,3.049999952316284,3.259999990463257,3.005000114440918,3.134999990463257,40004,0.0,0.0,3.233999991416931,3.3552500128746034,3.082875011364619,-3.0612245274094385,-3.6137402873829862,8.835097125440027,42.468224787847184,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2023-09-06,3.2049999237060547,3.2100000381469727,3.0999999046325684,3.1500000953674316,11244,0.0,0.0,3.219000005722046,3.3467500150203704,3.0822916785875956,-2.1435200444846525,-3.817136288189335,8.579925717930696,43.3730604651295,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2023-09-07,3.1500000953674316,3.299999952316284,3.1500000953674316,3.180000066757202,17442,0.0,0.0,3.206000018119812,3.340750014781952,3.0839583456516264,-0.8109778919420466,-4.033525288210922,8.326690582329077,45.22842147825538,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2023-09-08,3.25,3.5999999046325684,3.25,3.375,135083,0.0,0.0,3.203500008583069,3.3427500128746033,3.086250013113022,5.353519305679251,-4.165731919982436,8.3110570651033,55.44681067410748,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2023-09-11,3.369999885559082,3.5,3.174999952316284,3.369999885559082,134129,0.0,0.0,3.206500005722046,3.3415000081062316,3.08916667898496,5.099013863878622,-4.040101812260527,8.16833001721304,55.16262494079259,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2023-09-12,3.375,3.375,3.1649999618530273,3.325000047683716,106584,0.0,0.0,3.209000015258789,3.338750010728836,3.0923750122388203,3.614834274644653,-3.8861848012910456,7.967177250977884,52.55207928240428,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2023-09-13,3.3299999237060547,3.3299999237060547,3.200000047683716,3.2049999237060547,42379,0.0,0.0,3.2134999990463258,3.333500009775162,3.0953333457310994,-0.26451144679613076,-3.5998203202924217,7.694378518957509,46.26442101632754,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2023-09-14,3.3299999237060547,3.3299999237060547,3.2100000381469727,3.2249999046325684,9731,0.0,0.0,3.2209999799728393,3.329625004529953,3.0977916777133943,0.12418269744176842,-3.2623801301747,7.48382560662324,47.39412801592635,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2023-09-15,3.3399999141693115,3.3399999141693115,3.1050000190734863,3.200000047683716,50076,0.0,0.0,3.230999994277954,3.32425000667572,3.0996250112851462,-0.959453625785778,-2.805144384763559,7.24684420124231,46.08975761047216,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2023-09-18,3.194999933242798,3.25,3.049999952316284,3.115000009536743,30347,0.0,0.0,3.2279999971389772,3.315500009059906,3.100916677713394,-3.5006191977195655,-2.63911964053165,6.919996686423216,41.87036951356586,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2023-09-19,3.115000009536743,3.174999952316284,3.0399999618530273,3.174999952316284,68975,0.0,0.0,3.23199999332428,3.3095000088214874,3.1035416781902314,-1.763615133840644,-2.3417439278027192,6.636235371949524,45.652536730174425,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2023-09-20,3.180000066757202,3.3550000190734863,3.0999999046325684,3.184999942779541,38770,0.0,0.0,3.2354999780654907,3.304625004529953,3.1072500109672547,-1.5608108678196853,-2.091766126858759,6.35207958374928,46.27989189044118,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2023-09-21,3.184999942779541,3.184999942779541,3.005000114440918,3.005000114440918,144856,0.0,0.0,3.217999982833862,3.2950000047683714,3.1059583445390064,-6.619013969209858,-2.336874713902228,6.086419689489524,37.81764222685371,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2023-09-22,3.005000114440918,3.1050000190734863,2.7850000858306885,2.934999942779541,188502,0.0,0.0,3.1739999771118166,3.2826250016689302,3.1042500098546344,-7.529931822802148,-3.30909027080118,5.746154183716948,35.12763119861215,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2023-09-25,2.934999942779541,3.0299999713897705,2.7200000286102295,2.880000114440918,198991,0.0,0.0,3.125,3.268875002861023,3.10191667675972,-7.839996337890626,-4.401361408285695,5.3824245941934405,33.13341290182616,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2023-09-26,2.9200000762939453,3.174999952316284,2.9200000762939453,3.0,117281,0.0,0.0,3.0924999952316283,3.2596250057220457,3.101083344221115,-2.9911073686097156,-5.127123831638333,5.11246051468993,41.003095850750604,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2023-09-27,2.9800000190734863,3.0799999237060547,2.7950000762939453,2.8949999809265137,81736,0.0,0.0,3.061500000953674,3.2473750054836272,3.0994166771570844,-5.438511186519509,-5.723854011811949,4.773747570534998,36.909716302205695,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2023-09-28,2.9000000953674316,3.0,2.7200000286102295,2.869999885559082,147195,0.0,0.0,3.0259999990463258,3.2342500030994414,3.095916676521301,-5.155324307217738,-6.438896308372756,4.468250958665249,35.98849075785297,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2023-09-29,2.8499999046325684,2.940000057220459,2.700000047683716,2.8499999046325684,80480,0.0,0.0,2.9909999847412108,3.2208750009536744,3.0956666747728985,-4.714145129654425,-7.137036244635373,4.044632040042274,35.23092231234041,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2023-10-02,2.8450000286102295,2.9200000762939453,2.7850000858306885,2.859999895095825,33581,0.0,0.0,2.9654999732971192,3.2072499990463257,3.0970833400885263,-3.5575814922026905,-7.5376109071974655,3.557109927647296,35.956837198065955,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2023-10-03,2.9000000953674316,3.049999952316284,2.880000114440918,2.934999942779541,32574,0.0,0.0,2.9414999723434447,3.1956249952316282,3.0993333399295806,-0.22097669981364143,-7.952279233870612,3.1068505623933778,41.27304681008325,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2023-10-04,2.944999933242798,2.994999885559082,2.7899999618530273,2.8499999046325684,43501,0.0,0.0,2.9079999685287476,3.1793749928474426,3.1020416716734567,-1.9945001555664879,-8.53548338680402,2.492981376754587,37.47616775433985,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2023-10-05,2.8499999046325684,2.880000114440918,2.7200000286102295,2.809999942779541,81792,0.0,0.0,2.88849995136261,3.1589999914169313,3.102458337942759,-2.7176738758827965,-8.562837631822589,1.822479057419513,35.8068041739014,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2023-10-06,2.7249999046325684,2.9100000858306885,2.7249999046325684,2.8949999809265137,8057,0.0,0.0,2.884499955177307,3.1426249921321867,3.105291670560837,0.3640154589137893,-8.213676070199801,1.2022484691303468,41.74523177047974,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2023-10-09,2.8949999809265137,2.930000066757202,2.799999952316284,2.930000066757202,50963,0.0,0.0,2.8894999504089354,3.132124996185303,3.1076666712760925,1.4016306296366268,-7.746339819511254,0.7870317989788473,44.04079203934028,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2023-10-10,2.930000066757202,3.0,2.825000047683716,2.880000114440918,22481,0.0,0.0,2.8774999618530273,3.1241249978542327,3.110000006357829,0.08688627701251775,-7.8942115366893715,0.4541797899526663,41.52348505119282,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2023-10-11,2.9000000953674316,2.944999933242798,2.8499999046325684,2.9000000953674316,23815,0.0,0.0,2.8779999732971193,3.1110000014305115,3.112291673819224,0.7644239845182609,-7.48955409920454,-0.041502292332625486,42.92870233478434,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2023-10-12,2.9000000953674316,3.0999999046325684,2.799999952316284,2.865000009536743,70610,0.0,0.0,2.877499985694885,3.1007499992847443,3.112916674216588,-0.4344040389325425,-7.199871438889193,-0.39084486368096544,41.068766871710366,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2023-10-13,2.865000009536743,2.865000009536743,2.5,2.6449999809265137,145088,0.0,0.0,2.85699999332428,3.0844999969005586,3.112791673342387,-7.420371469833019,-7.375587738851706,-0.9088843524002922,31.755411567854537,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2023-10-16,2.640000104904175,2.640000104904175,1.965999960899353,2.3299999237060547,258767,0.0,0.0,2.803999996185303,3.0639999926090242,3.1110416730244954,-16.904424861772494,-8.485639590433843,-1.512087762223325,23.528156138083816,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2023-10-17,2.325000047683716,2.5899999141693115,2.140000104904175,2.5899999141693115,105121,0.0,0.0,2.76949999332428,3.044249987602234,3.1125416715939838,-6.481317190382486,-9.025211313028782,-2.194080953678493,37.84267978627468,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2023-10-18,2.5899999141693115,2.5899999141693115,2.3949999809265137,2.450000047683716,83759,0.0,0.0,2.7295000076293947,3.0229999899864195,3.111708339055379,-10.239969194520286,-9.708897893788723,-2.8507925359061352,34.137217245397494,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2023-10-19,2.4000000953674316,2.549999952316284,2.4000000953674316,2.549999952316284,35654,0.0,0.0,2.703500008583069,3.0039999902248384,3.1118750055631,-5.67782710484383,-10.003328316232057,-3.4665600368078255,38.750595484827,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2023-10-20,2.5899999141693115,2.5899999141693115,2.384999990463257,2.509999990463257,14607,0.0,0.0,2.665000009536743,2.981749987602234,3.1120416720708213,-5.8161357793176816,-10.622955626142371,-4.18669472320685,37.61560628848233,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2023-10-23,2.5799999237060547,2.5799999237060547,2.200000047683716,2.2850000858306885,103712,0.0,0.0,2.6005000114440917,2.9553749918937684,3.1085000058015186,-12.132279339549088,-12.007781801736,-4.926009767475209,31.947281846166504,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2023-10-24,2.2850000858306885,2.4549999237060547,2.1549999713897705,2.3399999141693115,63692,0.0,0.0,2.546499991416931,2.931374990940094,3.103666671117147,-8.109172509076592,-13.129504096633271,-5.551230155622268,34.54385603024387,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2023-10-25,2.4000000953674316,2.4649999141693115,2.3399999141693115,2.444999933242798,22683,0.0,0.0,2.5009999752044676,2.913499987125397,3.0951250036557516,-2.23910605825142,-14.158229405997771,-5.868099553841335,39.30509746251021,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2023-10-26,2.4700000286102295,2.5,2.200000047683716,2.434999942779541,61968,0.0,0.0,2.4579999685287475,2.8956249833106993,3.088000003496806,-0.9357211571883491,-15.1133181024566,-6.229761009334977,39.01403543377747,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2023-10-27,2.434999942779541,2.890000104904175,2.434999942779541,2.5399999618530273,48975,0.0,0.0,2.447499966621399,2.8816249847412108,3.0835416694482167,3.7793665574311754,-15.065285053349822,-6.548206781429286,43.726169400254776,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2023-10-30,2.5999999046325684,2.5999999046325684,2.4000000953674316,2.4700000286102295,29566,0.0,0.0,2.4614999771118162,2.8647499859333037,3.077916669845581,0.34531999095879495,-14.076272303047524,-6.925680802234707,41.42803713585329,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2023-10-31,2.4800000190734863,2.640000104904175,2.4749999046325684,2.640000104904175,32114,0.0,0.0,2.466499996185303,2.8523749887943266,3.0740000049273175,7.034263490257764,-13.528199978086668,-7.209662191859074,48.50625948533431,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2023-11-01,2.680000066757202,2.7300000190734863,2.3499999046325684,2.444999933242798,134613,0.0,0.0,2.465999984741211,2.8347499847412108,3.0692500034968058,-0.8515836021230471,-13.008201851482282,-7.6403036079963655,42.205738186061964,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2023-11-02,2.440000057220459,2.684999942779541,2.200000047683716,2.4000000953674316,306061,0.0,0.0,2.4509999990463256,2.8152499854564668,3.0649583379427594,-2.0807794246731053,-12.938459756392874,-8.147202178738267,40.885922933988404,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2023-11-03,2.365000009536743,2.4000000953674316,2.299999952316284,2.375,86393,0.0,0.0,2.4375,2.790249985456467,3.06050000389417,-2.564102564102564,-12.642235903417065,-8.830257085242216,40.135025559507774,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2023-11-06,2.4800000190734863,2.5799999237060547,2.4200000762939453,2.505000114440918,70486,0.0,0.0,2.4595000028610228,2.7686249911785126,3.056791671117147,1.8499740405353535,-11.165289242943135,-9.427095822768965,45.717810398013825,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2023-11-07,2.505000114440918,2.5350000858306885,2.4149999618530273,2.4549999237060547,26988,0.0,0.0,2.471000003814697,2.746874988079071,3.0507916708787284,-0.6475143700502504,-10.04323041498504,-9.96189565156769,44.017545757510014,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2023-11-08,2.5,2.5,2.4149999618530273,2.484999895095825,41342,0.0,0.0,2.475,2.7288749873638154,3.0460416694482166,0.4040361654878831,-9.303283900486296,-10.412420987722577,45.33126921622551,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2023-11-09,2.549999952316284,2.549999952316284,2.424999952316284,2.494999885559082,40851,0.0,0.0,2.480999994277954,2.710624986886978,3.0408333361148836,0.5642842125520641,-8.471293289181155,-10.85914000304258,45.7879484800248,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2023-11-10,2.494999885559082,2.549999952316284,2.4800000190734863,2.490000009536743,46399,0.0,0.0,2.4759999990463255,2.6928749859333037,3.036833335955938,0.5654285337564622,-8.05365967673442,-11.326217542141231,45.58291784540062,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2023-11-13,2.490000009536743,2.494999885559082,2.4549999237060547,2.4649999141693115,22462,0.0,0.0,2.475499987602234,2.676624983549118,3.032083334525426,-0.42415970452468965,-7.514126826993856,-11.723238175178437,44.50969646449501,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2023-11-14,2.4200000762939453,2.484999895095825,2.4000000953674316,2.4649999141693115,38975,0.0,0.0,2.4579999685287475,2.6588749825954436,3.027791666984558,0.28478216965779374,-7.554887513763934,-12.184348362267814,44.509696464495015,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2023-11-15,2.4649999141693115,2.4800000190734863,2.4100000858306885,2.450000047683716,50491,0.0,0.0,2.4584999799728395,2.640499985218048,3.023208334048589,-0.3457365205761611,-6.892634208069476,-12.659013423597887,43.79223366692399,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2023-11-16,2.450000047683716,2.4549999237060547,2.240000009536743,2.315000057220459,153718,0.0,0.0,2.449999976158142,2.6232499837875367,3.017708335320155,-5.510200826588457,-6.604403266944868,-13.071453821953586,37.87488565084457,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2023-11-17,2.315000057220459,2.4049999713897705,2.2799999713897705,2.3550000190734863,84227,0.0,0.0,2.4479999780654906,2.6087499856948853,3.013166668017705,-3.7990179667197816,-6.161955285514878,-13.421649941085953,40.44276754938614,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2023-11-20,2.4049999713897705,2.575000047683716,2.380000114440918,2.509999990463257,95856,0.0,0.0,2.4484999656677244,2.599499982595444,3.009291668732961,2.5117429306869883,-5.808810076503831,-13.617546294874664,49.20449692395991,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2023-11-21,2.5450000762939453,2.5799999237060547,2.4600000381469727,2.5799999237060547,68324,0.0,0.0,2.4609999656677246,2.588999980688095,3.0078333338101704,4.835431113305307,-4.9439944370471185,-13.924752692048884,52.59620983564829,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2023-11-22,2.5799999237060547,2.6500000953674316,2.444999933242798,2.555000066757202,37744,0.0,0.0,2.467999982833862,2.5804999828338624,3.007291668653488,3.5251249808941587,-4.359620257639166,-14.191895327888874,51.279286853724635,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2023-11-23,2.559999942779541,2.890000104904175,2.559999942779541,2.7699999809265137,119614,0.0,0.0,2.4954999923706054,2.577999985218048,3.0078750014305116,10.99979921439096,-3.2001548999413565,-14.291651614778528,60.45059572478313,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2023-11-24,2.7699999809265137,3.2249999046325684,2.640000104904175,2.924999952316284,140256,0.0,0.0,2.5389999866485597,2.579874986410141,3.0090833346048993,15.202834489859072,-1.5843790872385692,-14.26375744595703,65.4936609309056,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2023-11-27,2.990000009536743,3.0950000286102295,2.9000000953674316,2.930000066757202,88004,0.0,0.0,2.5855000019073486,2.5816249907016755,3.0093333343664805,13.324311142746565,0.15009969378317478,-14.212727409768497,65.6458442066249,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2023-11-28,2.930000066757202,2.990000009536743,2.799999952316284,2.865000009536743,97262,0.0,0.0,2.6255000114440916,2.5798749923706055,3.0073333342870074,9.122071873879767,1.768497280233026,-14.213866385973665,61.82838485042371,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2023-11-29,3.5,3.9149999618530273,3.3350000381469727,3.5350000858306885,2951121,0.0,0.0,2.734000015258789,2.5969999969005584,3.0117916683355967,29.29773467817923,5.275318387436886,-13.772256421184148,76.80277230555842,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2023-11-30,3.5,3.559999942779541,3.0999999046325684,3.1549999713897705,595841,0.0,0.0,2.81800000667572,2.605624997615814,3.0133333345254263,11.958834773446137,8.150635999202963,-13.530143918638949,61.95728476017306,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2023-12-01,3.5199999809265137,3.5199999809265137,3.005000114440918,3.1649999618530273,166437,0.0,0.0,2.8990000009536745,2.612374997138977,3.014666666587194,9.175576433661528,10.97181699138154,-13.34448262247309,62.16454551007342,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2023-12-04,3.2200000286102295,3.5899999141693115,3.1449999809265137,3.2100000381469727,515478,0.0,0.0,2.969000005722046,2.6193749964237214,3.0162500003973642,8.11721225868832,13.347650098808822,-13.157894866849832,63.13779725225937,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2023-12-05,3.2100000381469727,3.315000057220459,2.9700000286102295,3.200000047683716,279229,0.0,0.0,3.031000018119812,2.627374994754791,3.018083333969116,5.5757185270073935,15.362292180248547,-12.945578235591663,62.75150022430164,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2023-12-06,3.259999990463257,3.259999990463257,3.0799999237060547,3.0999999046325684,116106,0.0,0.0,3.0855000019073486,2.6323749899864195,3.0186249991257985,0.46993688919968857,17.213543421610566,-12.795561199262512,58.872413411558064,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2023-12-07,3.0999999046325684,3.1700000762939453,3.0,3.1700000762939453,108164,0.0,0.0,3.1255000114440916,2.63999999165535,3.020041666428248,1.4237742660987254,18.390152322853623,-12.58398779717391,60.70363513097727,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2023-12-08,3.1700000762939453,3.484999895095825,3.0250000953674316,3.365000009536743,271538,0.0,0.0,3.1695000171661376,2.6579999923706055,3.023083333174388,6.168165051641264,19.243793313157152,-12.076522562162607,65.33415297895476,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2023-12-11,3.369999885559082,3.490000009536743,3.200000047683716,3.390000104904175,129517,0.0,0.0,3.215500020980835,2.6844999969005583,3.025500001509984,5.426841324358367,19.780220700069027,-11.27086446667452,65.8891134849735,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2023-12-12,3.2750000953674316,3.4200000762939453,3.200000047683716,3.25,113577,0.0,0.0,3.254000020027161,2.7009999990463256,3.0264166673024495,-0.12292624470012863,20.473899340099578,-10.75254018298079,60.08790220719179,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2023-12-13,3.25,3.25,3.0850000381469727,3.2049999237060547,90076,0.0,0.0,3.221000003814697,2.719874995946884,3.0276666661103566,-0.4967426292981426,18.42456026893081,-10.165969510735229,58.310755588159964,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2023-12-14,3.2049999237060547,3.5999999046325684,3.2049999237060547,3.3550000190734863,146521,0.0,0.0,3.241000008583069,2.739999997615814,3.0302083333333334,3.5174332054462694,18.284671949021735,-9.577174365377058,62.312059940255345,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2023-12-15,3.3550000190734863,3.3550000190734863,3.2300000190734863,3.2799999713897705,92797,0.0,0.0,3.2525000095367433,2.7592499971389772,3.031958333651225,0.8455022835478488,17.876234951860443,-8.994461879159124,59.24995362602499,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2023-12-18,3.2799999713897705,3.299999952316284,3.180000066757202,3.259999990463257,46882,0.0,0.0,3.2575000047683718,2.783624994754791,3.033291667699814,0.07674553158021685,17.023665576595537,-8.230882496517337,58.42543057157968,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2023-12-19,3.259999990463257,3.390000104904175,3.0,3.140000104904175,329656,0.0,0.0,3.2515000104904175,2.803624999523163,3.0332083344459533,-3.42918361453197,15.974854377580042,-7.568993277368335,53.60530356028071,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2023-12-20,3.119999885559082,3.1500000953674316,3.0299999713897705,3.1500000953674316,60735,0.0,0.0,3.2565000295639037,2.821250003576279,3.0332083344459533,-3.2703802619259945,15.427559607829588,-6.987925242806996,53.94628026669601,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2023-12-21,3.1500000953674316,3.1500000953674316,3.0250000953674316,3.134999990463257,31376,0.0,0.0,3.253000020980835,2.8387500047683716,3.0337916672229768,-3.6274217570401093,14.592690991338781,-6.4289735040751586,53.31332713303887,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2023-12-22,3.140000104904175,3.2200000286102295,3.0450000762939453,3.119999885559082,80331,0.0,0.0,3.228500008583069,2.853250002861023,3.0331666668256125,-3.360697622287001,13.151669336573155,-5.931644506461719,52.6480886834622,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2023-12-27,3.0999999046325684,3.0999999046325684,3.0350000858306885,3.0899999141693115,107635,0.0,0.0,3.1984999895095827,2.86875,3.0312916656335194,-3.392217467441893,11.494553011227287,-5.3621255742656935,51.27018868524253,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2023-12-28,3.0899999141693115,3.140000104904175,3.0399999618530273,3.0399999618530273,30672,0.0,0.0,3.1774999856948853,2.8787499964237213,3.028791666030884,-4.327302107344879,10.37776776872955,-4.953845828682776,48.96982210487502,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2023-12-29,3.059999942779541,3.0950000286102295,3.009999990463257,3.0350000858306885,51227,0.0,0.0,3.160500001907349,2.8935000002384186,3.025,-3.970888024075989,9.227579113424225,-4.34710743013492,48.73434882655823,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2024-01-02,3.0350000858306885,3.0999999046325684,3.0,3.0999999046325684,65448,0.0,0.0,3.134999990463257,2.910999995470047,3.022333331902822,-1.1164301734341167,7.694950028917461,-3.68368820399703,51.96791767646121,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2024-01-03,3.0350000858306885,3.0999999046325684,3.0350000858306885,3.0450000762939453,49441,0.0,0.0,3.1115000009536744,2.9277499973773957,3.0202499985694886,-2.137230423890306,6.276150755388174,-3.0626604167173115,49.14333598342186,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2024-01-04,3.0450000762939453,3.200000047683716,3.0450000762939453,3.1549999713897705,49533,0.0,0.0,3.1009999990463255,2.9439999938011168,3.0180416643619536,1.7413728590793949,5.332880624177575,-2.45330180279304,54.4730400621826,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2024-01-05,3.1549999713897705,3.1549999713897705,3.0899999141693115,3.140000104904175,9747,0.0,0.0,3.1009999990463255,2.96112499833107,3.015583332379659,1.2576622337904968,4.723711454061913,-1.8058971696734543,53.64741319152873,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2024-01-08,3.125,3.140000104904175,3.055000066757202,3.069999933242798,24753,0.0,0.0,3.092999982833862,2.9757499992847443,3.0127083321412402,-0.743616221102957,3.9401825952213807,-1.226747789097405,49.850195736503146,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2024-01-09,3.049999952316284,3.075000047683716,2.859999895095825,3.005000114440918,163666,0.0,0.0,3.0799999952316286,2.9885000050067902,3.0095833321412404,-2.4350610684033565,3.0617363249638156,-0.7005397361584242,46.55500339319912,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2024-01-10,3.005000114440918,3.0950000286102295,2.930000066757202,3.065000057220459,113307,0.0,0.0,3.074500012397766,3.002875006198883,3.0066666662693025,-0.30899187311754306,2.3852143712617453,-0.12610842807939318,49.850379057958776,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2024-01-11,3.1050000190734863,3.1050000190734863,2.9600000381469727,2.9600000381469727,42809,0.0,0.0,3.0615000247955324,3.0152500092983248,3.002458333969116,-3.3153678205617063,1.5338700059558388,0.42604006138857975,44.66063441169103,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2024-01-12,2.9600000381469727,3.049999952316284,2.9100000858306885,3.0350000858306885,63223,0.0,0.0,3.061000037193298,3.029500013589859,2.9992916683355966,-0.8493940230869662,1.0397763149739208,1.0071826482626183,48.76373210267531,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2024-01-15,2.9549999237060547,3.005000114440918,2.890000104904175,2.9200000762939453,139268,0.0,0.0,3.049500036239624,3.0412500143051147,2.995458334684372,-4.2465964389810775,0.2712707569487413,1.5287036074086382,43.444668437702425,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2024-01-16,2.9200000762939453,2.944999933242798,2.700000047683716,2.700000047683716,103552,0.0,0.0,3.0095000505447387,3.0508750140666963,2.989708334207535,-10.284100271239451,-1.3561671104581363,2.0459079288540223,35.47305263471927,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2024-01-17,2.7100000381469727,2.7149999141693115,2.509999990463257,2.640000104904175,131661,0.0,0.0,2.969000053405762,3.058000016212463,2.983125001192093,-11.081170177959034,-2.910397721872274,2.509952314785647,33.659103126130745,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2024-01-18,2.640000104904175,2.9549999237060547,2.6050000190734863,2.7899999618530273,77392,0.0,0.0,2.9325000524520872,3.0650000154972075,2.977791666984558,-4.859338040928752,-4.323000403757779,2.9286249095108907,41.68724247335148,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2024-01-19,2.7899999618530273,2.8550000190734863,2.6500000953674316,2.694999933242798,35316,0.0,0.0,2.8880000352859496,3.067875015735626,2.9721666673819223,-6.6828289364630225,-5.863178243150996,3.2201541523245036,38.508821849821445,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2024-01-22,2.7300000190734863,2.809999942779541,2.700000047683716,2.809999942779541,103516,0.0,0.0,2.862000036239624,3.0742500126361847,2.9673750003178916,-1.816914493418583,-6.90412216066173,3.6016685557721457,44.06819540651469,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2024-01-23,2.809999942779541,2.875,2.6700000762939453,2.680000066757202,57628,0.0,0.0,2.8295000314712526,3.0720000147819517,2.961416667699814,-5.2836177081190945,-7.893879627077788,3.734136715318412,39.698810698490725,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2024-01-24,2.680000066757202,2.7950000762939453,2.5999999046325684,2.6649999618530273,43422,0.0,0.0,2.789500021934509,3.0655000150203704,2.955416667461395,-4.463167560584619,-9.003424946452892,3.7247995780416723,39.2156512342945,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2024-01-25,2.75,2.75,2.640000104904175,2.6549999713897705,53401,0.0,0.0,2.7590000152587892,3.0586250126361847,2.9491666674613954,-3.7694832654527444,-9.796068368614856,3.711500824367094,38.87596019070578,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2024-01-26,2.634999990463257,2.6500000953674316,2.515000104904175,2.5950000286102295,137353,0.0,0.0,2.7150000095367433,3.0518750131130217,2.942458333571752,-4.41988878471456,-11.038296199183264,3.7185464376126824,36.815378357336684,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2024-01-29,2.5950000286102295,2.6549999713897705,2.509999990463257,2.6500000953674316,71704,0.0,0.0,2.6880000114440916,3.0297500133514403,2.935375001033147,-1.413687348023672,-11.279808578309492,3.215092187031529,39.957098335593116,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2024-01-30,2.7249999046325684,2.950000047683716,2.015000104904175,2.3550000190734863,1141527,0.0,0.0,2.6535000085830687,3.0097500145435334,2.9247916678587598,-11.249292954363966,-11.83653141420433,2.904765751981633,31.041629430723148,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2024-01-31,2.3550000190734863,2.490000009536743,2.0250000953674316,2.380000114440918,337519,0.0,0.0,2.6275000095367433,2.9901250183582304,2.9150416692097982,-9.419596353853574,-12.12741964282789,2.5757212989955502,32.41784511465106,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2024-02-01,2.380000114440918,2.380000114440918,2.200000047683716,2.259999990463257,190320,0.0,0.0,2.574500012397766,2.9663750171661376,2.9059583365917208,-12.215965058069619,-13.210568539062905,2.079062174211248,29.38626774783586,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2024-02-02,2.2750000953674316,2.369999885559082,2.1500000953674316,2.2799999713897705,190737,0.0,0.0,2.5330000162124633,2.943375015258789,2.898291669289271,-9.98815804198051,-13.942328005058657,1.555514458645682,30.551941961453835,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2024-02-05,2.200000047683716,2.25,2.065000057220459,2.174999952316284,126029,0.0,0.0,2.469500017166138,2.920250016450882,2.8878750026226045,-11.925493533213485,-15.435322206848637,1.121067005977616,27.943872830311136,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2024-02-06,2.180000066757202,2.2249999046325684,2.0450000762939453,2.0450000762939453,92020,0.0,0.0,2.406000018119812,2.892125016450882,2.8776250024636587,-15.004153745101506,-16.808574856408736,0.5038882402957039,25.08832057194428,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2024-02-07,2.109999895095825,2.194999933242798,2.0450000762939453,2.109999895095825,120816,0.0,0.0,2.3505000114440917,2.860750013589859,2.8677500009536745,-10.231870460639092,-17.836231747683247,-0.24409336104917506,28.995328819508757,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2024-02-08,2.115000009536743,2.240000009536743,2.115000009536743,2.174999952316284,33815,0.0,0.0,2.302500009536743,2.8303750097751617,2.8596249997615812,-5.537461745596763,-18.650355462273236,-1.0228610390823372,32.77135855778799,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2024-02-09,2.200000047683716,2.3450000286102295,2.109999895095825,2.134999990463257,86802,0.0,0.0,2.256500005722046,2.802500009536743,2.849249998728434,-5.384445599410087,-19.48260488694706,-1.6407822834975716,31.655700924748785,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2024-02-12,2.184999942779541,2.200000047683716,2.069999933242798,2.130000114440918,35788,0.0,0.0,2.2045000076293944,2.7756250143051147,2.839500000079473,-3.3794462658491766,-20.576446880693034,-2.2495152587628313,31.511294312629005,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2024-02-13,2.200000047683716,2.200000047683716,2.109999895095825,2.125,90905,0.0,0.0,2.1815000057220457,2.7448750138282776,2.82962500055631,-2.589961291489661,-20.52461424538572,-2.9950960537658013,31.357238409183665,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2024-02-14,2.194999933242798,2.194999933242798,2.0799999237060547,2.115000009536743,40305,0.0,0.0,2.1549999952316283,2.715750014781952,2.8189166665077208,-1.8561478321760183,-20.648072042645147,-3.6597978560884217,31.030496269093007,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2024-02-15,2.065000057220459,2.125,2.065000057220459,2.0999999046325684,41521,0.0,0.0,2.1389999866485594,2.6867500126361845,2.808583333094915,-1.823285753128843,-20.387085639210024,-4.337892311155897,30.51682406111567,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2024-02-16,2.130000114440918,2.130000114440918,2.0199999809265137,2.0799999237060547,156201,0.0,0.0,2.118999981880188,2.6602500081062317,2.7984166661898295,-1.8404935586421514,-20.345833082483352,-4.937315438151602,29.80830012513981,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2024-02-19,2.119999885559082,2.130000114440918,2.005000114440918,2.130000114440918,49938,0.0,0.0,2.1144999980926515,2.634750008583069,2.7898333330949145,0.7330393172025557,-19.74570675759103,-5.558874169010064,33.93777790263958,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2024-02-20,2.130000114440918,2.194999933242798,2.0899999141693115,2.0999999046325684,55597,0.0,0.0,2.1199999809265138,2.6088750064373016,2.7810833315054575,-0.9433998336738038,-18.738920964189816,-6.192131070554292,32.69490486822761,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2024-02-21,2.200000047683716,2.200000047683716,2.0999999046325684,2.1449999809265137,11191,0.0,0.0,2.1234999895095825,2.5845000088214873,2.773124998807907,1.0124789980289346,-17.837106509514673,-6.801892812891765,36.45417902175616,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2024-02-22,2.1449999809265137,2.1549999713897705,2.0999999046325684,2.1500000953674316,31585,0.0,0.0,2.1210000038146974,2.5610000133514403,2.7648333330949146,1.3672838991313745,-17.180789037206566,-7.372354684226344,36.87607118223239,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2024-02-23,2.194999933242798,2.4200000762939453,2.0899999141693115,2.244999885559082,214286,0.0,0.0,2.1319999933242797,2.541125011444092,2.7574166655540466,5.300182579203925,-16.1001531320693,-7.843996042088737,44.42555073543624,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2024-02-26,2.2699999809265137,2.2699999809265137,2.0999999046325684,2.0999999046325684,89652,0.0,0.0,2.1289999723434447,2.517750006914139,2.7486666639645896,-1.3621450487364386,-15.440374679897737,-8.401042588313846,37.126912911502245,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2024-02-27,2.2200000286102295,2.2300000190734863,2.055000066757202,2.119999885559082,53713,0.0,0.0,2.128499960899353,2.4932500064373015,2.739833329121272,-0.39934580673797876,-14.629501437730003,-8.999938794198675,38.62469615627663,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2024-02-28,2.119999885559082,2.325000047683716,2.115000009536743,2.255000114440918,168975,0.0,0.0,2.1424999713897703,2.473500007390976,2.730499996741613,5.250881892809195,-13.381848999885035,-9.41219518979391,47.684239954636595,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2024-02-29,2.1700000762939453,2.1700000762939453,2.069999933242798,2.119999885559082,134438,0.0,0.0,2.144499969482422,2.4476250052452087,2.7200833300749463,-1.1424613789690634,-12.384455752543632,-10.016543310172436,41.14386764210399,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2024-03-01,2.119999885559082,2.3299999237060547,2.069999933242798,2.1050000190734863,64652,0.0,0.0,2.146999979019165,2.4217500030994414,2.709916663169861,-1.9562161320963718,-11.345102662481333,-10.63378309698068,40.47951227215409,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2024-03-04,2.1050000190734863,2.1050000190734863,2.0199999809265137,2.065000057220459,86282,0.0,0.0,2.140499973297119,2.396625006198883,2.7004166642824807,-3.527209391194889,-10.686904803183443,-11.249806820619561,38.68559866271668,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2024-03-05,2.065000057220459,2.065000057220459,2.0,2.0250000953674316,29933,0.0,0.0,2.1329999923706056,2.372125005722046,2.690416665871938,-5.063286328620347,-10.08062445168878,-11.830571234093092,36.923408695735986,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2024-03-06,2.0250000953674316,2.075000047683716,1.9700000286102295,2.0450000762939453,37815,0.0,0.0,2.1230000019073487,2.346625006198883,2.680791666110357,-3.6740426539484976,-9.529643794845914,-12.465223021090868,38.43349778821938,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2024-03-07,2.0450000762939453,2.049999952316284,1.972000002861023,1.996000051498413,79666,0.0,0.0,2.1075999975204467,2.3225250065326692,2.671466666460037,-5.295119859239368,-9.253937348691336,-13.061801006476742,36.15003232943562,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2024-03-08,2.0,2.0399999618530273,1.909999966621399,1.934000015258789,96981,0.0,0.0,2.0765000104904177,2.2950000047683714,2.6611250003178912,-6.862508765312919,-9.520696898647998,-13.758278754503584,33.44255797737105,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2024-03-11,1.9320000410079956,2.049999952316284,1.909999966621399,2.0350000858306885,75386,0.0,0.0,2.0700000286102296,2.27287500500679,2.651541668176651,-1.6908184683958483,-8.925918757065764,-14.280999907131509,41.172094672845176,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2024-03-12,2.0450000762939453,2.0450000762939453,1.8700000047683716,1.9119999408721924,146866,0.0,0.0,2.0492000341415406,2.2531750023365023,2.6424333333969114,-6.695300165111733,-9.052779654640373,-14.731055884766949,35.73008271451047,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2024-03-13,1.9119999408721924,2.0399999618530273,1.9119999408721924,1.968000054359436,66900,0.0,0.0,2.0205000281333922,2.236375001072884,2.6343750009934106,-2.598365406728427,-9.652896890545064,-15.10794779674279,39.64174346890586,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2024-03-14,1.9019999504089355,1.9700000286102295,1.878000020980835,1.9199999570846558,96512,0.0,0.0,2.00050003528595,2.2146250009536743,2.6263749996821084,-4.02399783960951,-9.66867824464714,-15.677502214202905,37.53308797230643,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2024-03-15,1.9179999828338623,1.9179999828338623,1.7660000324249268,1.850000023841858,43029,0.0,0.0,1.9750000357627868,2.193500003218651,2.6167916665474573,-6.32911441303601,-9.961247646922558,-16.17597872769478,34.63932781317301,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2024-03-18,1.8480000495910645,1.8480000495910645,1.784000039100647,1.7999999523162842,77839,0.0,0.0,1.9485000252723694,2.1682500034570693,2.6076666663090386,-7.621250758532954,-10.134900395910497,-16.850952176105064,32.699989688561104,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2024-03-19,1.8200000524520874,1.9320000410079956,1.7999999523162842,1.8899999856948853,25414,0.0,0.0,1.9350000143051147,2.1485000014305116,2.599500000476837,-2.3255828567210415,-9.93716485842423,-17.349490246724248,39.28883585891796,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2024-03-20,2.0199999809265137,2.0199999809265137,1.8519999980926514,1.8960000276565552,25991,0.0,0.0,1.9201000094413758,2.1292750030755996,2.591550001502037,-1.255142006474557,-9.823765992278313,-17.837780407806424,39.71259310950443,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2024-03-21,1.8960000276565552,1.9119999408721924,1.8320000171661377,1.8700000047683716,82132,0.0,0.0,1.9075000047683717,2.1096500039100645,2.583300002415975,-1.9659239793581929,-9.582158119452245,-18.33507521631013,38.459854830059726,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2024-03-22,1.8639999628067017,1.8639999628067017,1.8040000200271606,1.8200000524520874,33488,0.0,0.0,1.8961000084877013,2.090275004506111,2.5740083366632462,-4.013499060965145,-9.289447350220282,-18.792997880659982,36.10135347704814,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2024-03-25,1.8040000200271606,1.8980000019073486,1.8040000200271606,1.878000020980835,89881,0.0,0.0,1.880400002002716,2.0709750026464464,2.565908337632815,-0.12763140923872626,-9.202187394835736,-19.288815883538945,40.6481507925153,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2024-03-26,1.840000033378601,2.009999990463257,1.8279999494552612,1.899999976158142,62360,0.0,0.0,1.879200005531311,2.0596000015735627,2.558325004577637,1.1068524140915121,-8.758982127812375,-19.4942003893837,42.32457326403595,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2024-03-27,1.8700000047683716,1.9359999895095825,1.8700000047683716,1.8700000047683716,52697,0.0,0.0,1.8694000005722047,2.046849998831749,2.5497833381096524,0.03209608409025613,-8.669418783048327,-19.72455195549149,40.638894438210336,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2024-03-28,1.8600000143051147,1.8700000047683716,1.8279999494552612,1.8459999561309814,8250,0.0,0.0,1.8620000004768371,2.036499997973442,2.5407500038544337,-0.859293466259841,-8.568622522477444,-19.846502218479635,39.29071367631502,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2024-04-02,1.8459999561309814,1.9279999732971191,1.8300000429153442,1.8300000429153442,31290,0.0,0.0,1.8600000023841858,2.0252499997615816,2.5320000032583874,-1.6129010446444645,-8.159486354615455,-20.01382317711998,38.37667664239986,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2024-04-03,1.8300000429153442,1.9759999513626099,1.75,1.850000023841858,76419,0.0,0.0,1.8650000095367432,2.017125001549721,2.523250002662341,-0.8042887730928847,-7.541674011085223,-20.058456378820793,40.247891878752384,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2024-04-04,1.850000023841858,1.9079999923706055,1.8339999914169312,1.850000023841858,33170,0.0,0.0,1.8610000133514404,2.0122500002384185,2.5147916694482166,-0.5910794965429794,-7.516461019707167,-19.98343144345088,40.24789187875238,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2024-04-05,1.850000023841858,1.9199999570846558,1.722000002861023,1.7979999780654907,63109,0.0,0.0,1.851200008392334,2.00445000231266,2.5077333360910417,-2.8738132068746314,-7.645488475318022,-20.069252441445002,36.871784173854905,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2024-04-08,1.7979999780654907,1.7979999780654907,1.722000002861023,1.74399995803833,60193,0.0,0.0,1.8386000037193297,1.9936750024557113,2.5028500030438106,-5.145221662658105,-7.778348955841234,-20.343808057569262,33.70950366108356,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2024-04-09,1.74399995803833,1.7999999523162842,1.7259999513626099,1.746000051498413,41100,0.0,0.0,1.8312000036239624,1.9839500039815903,2.4958166708548863,-4.652684139194943,-7.699286778954803,-20.508985008821483,33.935507281138314,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2024-04-10,1.7999999523162842,2.0,1.690000057220459,1.7200000286102295,271610,0.0,0.0,1.8154000043869019,1.973700001835823,2.4897333373626074,-5.255038864500328,-8.020469032866169,-20.7264500090368,32.38961905708416,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2024-04-11,1.850000023841858,2.0,1.753999948501587,1.8200000524520874,429335,0.0,0.0,1.8074000120162963,1.9660750031471252,2.483650004863739,0.6971362372480441,-8.07064790899816,-20.83928897803818,43.12164736244732,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2024-04-12,1.8200000524520874,1.9800000190734863,1.8200000524520874,1.8799999952316284,126915,0.0,0.0,1.8084000110626222,1.9602000027894975,2.4784000049034756,3.959300139958186,-7.744107311032222,-20.908650786343106,48.41275037193948,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2024-04-15,1.9500000476837158,1.9500000476837158,1.7879999876022339,1.899999976158142,100488,0.0,0.0,1.8138000130653382,1.9552000045776368,2.475191670656204,4.752451343691699,-7.231996275636457,-21.008137359346843,50.079764428615796,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2024-04-16,1.8799999952316284,1.8799999952316284,1.7799999713897705,1.7979999780654907,87462,0.0,0.0,1.8106000065803527,1.9481500059366226,2.470675004522006,-0.6959034833242609,-7.060544564695325,-21.149078597104868,42.53126755535777,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2024-04-17,1.8799999952316284,1.8799999952316284,1.7660000324249268,1.7699999809265137,63491,0.0,0.0,1.8026000022888184,1.9391500025987625,2.46505000491937,-1.8085000178027013,-7.041745101046633,-21.334252906476408,40.716939422626815,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2024-04-18,1.753999948501587,1.753999948501587,1.7000000476837158,1.75,132284,0.0,0.0,1.7925999999046325,1.9304000049829484,2.459341672062874,-2.3764364558127204,-7.138417153056997,-21.507449456433356,39.423289849477854,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2024-04-19,1.75,1.7799999713897705,1.7339999675750732,1.7339999675750732,33085,0.0,0.0,1.7861999988555908,1.9201250046491622,2.452625005443891,-2.922406858916237,-6.974806612553943,-21.71143161358879,38.37291978906505,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2024-04-22,1.7339999675750732,2.1449999809265137,1.7339999675750732,1.871999979019165,205936,0.0,0.0,1.7990000009536744,1.9131750017404556,2.4476416716972986,4.057808672973449,-5.967828383860014,-21.835985068280895,50.59856929066605,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2024-04-23,1.899999976158142,1.899999976158142,1.8040000200271606,1.8339999914169312,76831,0.0,0.0,1.8077999949455261,1.9029000043869018,2.440925004084905,1.4492751711836633,-4.9976356730324385,-22.04184883999363,47.787303610105454,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2024-04-24,1.8339999914169312,1.8339999914169312,1.6979999542236328,1.75,222480,0.0,0.0,1.8107999920845033,1.8941500067710877,2.4351333379745483,-3.3576315634126614,-4.400391436191963,-22.215758076452193,42.205061581443374,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2024-04-25,1.7480000257492065,1.75,1.6660000085830688,1.7000000476837158,125626,0.0,0.0,1.798799991607666,1.8836500108242036,2.4293000042438506,-5.4925474974929465,-4.504553326199429,-22.461202505512993,39.264871876936915,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2024-04-26,1.222000002861023,1.222000002861023,1.00600004196167,1.156000018119812,1225606,0.0,0.0,1.7263999938964845,1.8561750084161759,2.419141671061516,-33.039850428247505,-6.991529027773353,-23.271339143949806,21.618612737662218,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2024-04-29,1.156000018119812,1.1679999828338623,1.1200000047683716,1.1640000343322754,210486,0.0,0.0,1.6527999997138978,1.8322750121355056,2.407966670393944,-29.57405405773442,-9.795200569396552,-23.907791803623887,22.172546600749072,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2024-04-30,1.1640000343322754,1.1640000343322754,1.100000023841858,1.1200000047683716,46957,0.0,0.0,1.5850000023841857,1.8076500117778778,2.396841671069463,-29.337539237624778,-12.317097222526453,-24.582001656733954,21.281709561194518,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2024-05-02,1.1200000047683716,1.159999966621399,1.0920000076293945,1.1239999532699585,95311,0.0,0.0,1.5203999996185302,1.7841250091791152,2.385500004887581,-26.072089348068197,-14.781756222448008,-25.2095994330885,21.59012744477087,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2024-05-03,1.1360000371932983,1.2660000324249268,1.1239999532699585,1.2619999647140503,87841,0.0,0.0,1.4715999960899353,1.7650500059127807,2.3752250055472057,-14.243002985376165,-16.625591843846387,-25.689145163485367,31.553864089994207,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2024-05-06,1.2619999647140503,1.2799999713897705,1.149999976158142,1.1699999570846558,145401,0.0,0.0,1.4151999950408936,1.7431750029325486,2.364225005110105,-17.326175721838702,-18.814806737126315,-26.268650438735776,28.915829021559475,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2024-05-07,1.2979999780654907,1.2979999780654907,1.149999976158142,1.1579999923706055,94140,0.0,0.0,1.3437999963760376,1.7222250014543534,2.3533333390951157,-13.82646260652612,-21.97302935207364,-26.817634678282797,28.580191933973197,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2024-05-08,1.1579999923706055,1.159999966621399,1.1119999885559082,1.159999966621399,67132,0.0,0.0,1.2763999938964843,1.7028750002384185,2.3424583395322163,-9.119400488223864,-25.044410557570213,-27.303936573809935,28.728675450552473,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2024-05-10,1.159999966621399,1.159999966621399,1.1200000047683716,1.1260000467300415,56058,0.0,0.0,1.2139999985694885,1.6801499992609024,2.3314250061909356,-7.248760456601428,-27.744546671218234,-27.934632475872835,27.675283916633575,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2024-05-13,1.1260000467300415,1.1419999599456787,1.0759999752044678,1.100000023841858,299129,0.0,0.0,1.1539999961853027,1.659850001335144,2.321300005912781,-4.679373702075279,-30.475645675389195,-28.494809067884425,26.864086031018488,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2024-05-14,1.0980000495910645,1.350000023841858,1.0700000524520874,1.1759999990463257,476595,0.0,0.0,1.1559999942779542,1.6400499999523164,2.311475005745888,1.7301042272810423,-29.514344421721027,-29.0474698677051,33.04225716221421,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2024-05-15,1.1740000247955322,1.1740000247955322,1.1399999856948853,1.1660000085830688,30409,0.0,0.0,1.1561999917030334,1.6212000012397767,2.300275005896886,0.8476056867636188,-28.682458005251966,-29.52147038576961,32.65141441398977,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2024-05-16,1.1579999923706055,1.1579999923706055,1.1200000047683716,1.149999976158142,75960,0.0,0.0,1.1591999888420106,1.6037000000476838,2.28835833966732,-0.7936518954817194,-27.717154779101865,-29.91919262606273,31.999219073874144,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2024-05-17,1.1920000314712524,1.2200000286102295,1.1399999856948853,1.1399999856948853,109606,0.0,0.0,1.1607999920845031,1.5872000008821487,2.276566672325134,-1.791868240132077,-26.86491989419462,-30.280978801245123,31.57471820631163,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2024-05-20,1.1399999856948853,1.1799999475479126,1.1039999723434448,1.1799999475479126,55142,0.0,0.0,1.1525999903678894,1.5694499999284743,2.263316672046979,2.377230384261726,-26.560260574059853,-30.65707422598362,35.27355872870115,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2024-05-21,1.2120000123977661,1.2239999771118164,1.1299999952316284,1.1959999799728394,164250,0.0,0.0,1.1551999926567078,1.5519499987363816,2.2489083389441173,3.531854880149409,-25.564612674552205,-30.990962510057834,36.74648048300806,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2024-05-22,0.9930040240287781,1.0529409646987915,0.9703249931335449,0.9784250259399414,142469,0.0,0.0,1.1372424960136414,1.5296606242656707,2.2326452136039734,-13.965136778690596,-25.653934083608494,-31.486623358466037,27.561574874769903,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2024-05-23,0.9719449877738953,1.4417190551757812,0.9492660164833069,1.109637975692749,873462,0.0,0.0,1.1322062969207765,1.5119015723466873,2.2180171966552735,-1.993304690974228,-25.11375623722446,-31.835444079216103,37.67851586766513,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2024-05-24,1.2959270477294922,1.4967960119247437,1.142035961151123,1.4579180479049683,471083,0.0,0.0,1.1653980970382691,1.5013995230197907,2.200708179672559,25.100431484323373,-22.37921491447634,-31.776528260862726,55.45997172459777,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2024-05-27,1.6199090480804443,1.6725560426712036,1.4595379829406738,1.5389139652252197,363283,0.0,0.0,1.2092894911766052,1.4923723727464675,2.1872407962878544,27.25769771867438,-18.968649295543745,-31.769178076812803,58.43043504593525,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2024-05-28,1.590751051902771,1.5923709869384766,1.1776740550994873,1.2959270477294922,739405,0.0,0.0,1.2212821960449218,1.4780205488204956,2.1716651886701586,6.112006866742592,-17.370418359911074,-31.940680518732417,48.07246708850032,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2024-05-29,1.2959270477294922,1.4255199432373047,1.2959270477294922,1.2959270477294922,249457,0.0,0.0,1.2342748999595643,1.4642687261104583,2.1557145804166793,4.995009440113192,-15.707077672950604,-32.07501867768464,48.07246708850032,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2024-05-30,1.2959270477294922,1.3007869720458984,1.2052119970321655,1.2392300367355347,153275,0.0,0.0,1.2431979060173035,1.4494994759559632,2.1393748303254445,-0.3191663421056001,-14.23260741799173,-32.24658646023879,45.87192805373695,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2024-05-31,1.468000054359436,1.468000054359436,1.2660000324249268,1.2979999780654907,202217,0.0,0.0,1.258997905254364,1.435699474811554,2.1243581642707188,3.0978663783596057,-12.307698975816873,-32.41725905930641,48.5033553499083,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2024-06-03,1.2799999713897705,1.3899999856948853,1.2300000190734863,1.2799999713897705,278480,0.0,0.0,1.2689979076385498,1.4214494735002519,2.1086081633965175,0.8669883287431263,-10.72507807725992,-32.58825901486598,47.73787509317243,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2024-06-04,1.2899999618530273,1.2899999618530273,1.1399999856948853,1.1699999570846558,433329,0.0,0.0,1.2663979053497314,1.405749472975731,2.09031649629275,-7.611979446416894,-9.912973136743643,-32.74944366229338,43.24613827315582,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2024-06-05,1.1699999570846558,1.25,1.1100000143051147,1.2400000095367432,746683,0.0,0.0,1.2925554037094116,1.3931494742631911,2.072399828831355,-4.066007075738763,-7.220622941912371,-32.77602830874577,46.684079420175756,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2024-06-07,1.2400000095367432,1.25,1.1799999475479126,1.2300000190734863,284071,0.0,0.0,1.3045916080474853,1.380249473452568,2.0555664956569673,-5.7176198676945615,-5.481463087671503,-32.85308568860309,46.25302798711219,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2024-06-10,1.2000000476837158,1.3899999856948853,1.1399999856948853,1.2000000476837158,546991,0.0,0.0,1.2787998080253602,1.3672494739294052,2.038858163356781,-6.162009084386857,-6.4691680333834904,-32.940432125088954,44.91322640442357,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2024-06-11,1.2400000095367432,1.2400000095367432,1.1399999856948853,1.1799999475479126,157450,0.0,0.0,1.2429084062576294,1.3512494713068008,2.0207331627607346,-5.061391361824711,-8.01784328872996,-33.130732141758,43.998204926614584,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2024-06-12,1.1799999475479126,1.1799999475479126,1.1299999952316284,1.149999976158142,269458,0.0,0.0,1.2283156991004944,1.3329994708299637,2.002983162800471,-6.375862736241471,-7.853249308815567,-33.449292256344755,42.59635093051178,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2024-06-13,1.1299999952316284,1.149999976158142,1.059999942779541,1.059999942779541,314751,0.0,0.0,1.2047229886054993,1.3119994699954987,1.9846498290697734,-12.012972873828803,-8.17656438461575,-33.89264691542856,38.62081424883095,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2024-06-14,1.059999942779541,1.100000023841858,1.0399999618530273,1.0700000524520874,137486,0.0,0.0,1.1877999901771545,1.2937994718551635,1.9673998286326726,-9.917489366833372,-8.192883362830377,-34.238101832389404,39.29871795497831,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2024-06-17,1.0700000524520874,1.1299999952316284,0.949999988079071,1.0199999809265137,439626,0.0,0.0,1.1599999904632567,1.2750494718551635,1.9496498276789984,-12.068966438597363,-9.02313862571252,-34.60110355442275,37.092811057229035,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2024-06-18,1.059999942779541,1.149999976158142,1.0499999523162842,1.149999976158142,211876,0.0,0.0,1.146999990940094,1.260049471259117,1.9331081608931224,0.26155058777194806,-8.971828717650041,-34.817435632936494,45.63697894786245,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2024-06-19,1.2400000095367432,1.4900000095367432,1.1100000143051147,1.25,349666,0.0,0.0,1.1549999952316283,1.2479494720697404,1.9175248285134634,8.225108671911292,-7.4481763018781635,-34.9187320282472,51.135027878437015,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2024-06-20,1.2999999523162842,1.2999999523162842,1.1799999475479126,1.1799999475479126,285930,0.0,0.0,1.1489999890327454,1.230649471282959,1.9016081621249517,2.697994674592096,-6.6346660162372295,-35.28375110108015,47.512623159379615,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2024-06-24,1.190000057220459,1.2999999523162842,1.059999942779541,1.059999942779541,233952,0.0,0.0,1.1319999814033508,1.2112994700670243,1.885108161966006,-6.360427544755845,-6.546646029597097,-35.743768208836194,42.017513053980146,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2024-06-25,1.100000023841858,1.2999999523162842,1.0800000429153442,1.190000057220459,951823,0.0,0.0,1.1309999823570251,1.1972994714975358,1.8697331617275874,5.216629158603219,-5.537419060044002,-35.964152746199325,48.911041812210236,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2024-06-26,1.190000057220459,1.2899999618530273,1.100000023841858,1.1299999952316284,106054,0.0,0.0,1.1259999871253967,1.1830494701862335,1.853316495815913,0.3552405108319268,-4.822239855435307,-36.16581556053101,46.18200030882626,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2024-06-27,1.149999976158142,1.190000057220459,1.1100000143051147,1.1699999570846558,177678,0.0,0.0,1.127999985218048,1.1833994686603546,1.837691494822502,3.723401810017662,-4.681384850123396,-35.60401884677296,48.254839112574096,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2024-06-28,1.1699999570846558,1.350000023841858,1.159999966621399,1.2100000381469727,542134,0.0,0.0,1.1429999947547913,1.184549468755722,1.8214831620454788,5.861771102331013,-3.507618305259577,-34.96786061829397,50.31567473260847,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2024-07-01,1.2200000286102295,1.2400000095367432,1.2000000476837158,1.2300000190734863,148905,0.0,0.0,1.158999991416931,1.1872994691133498,1.8055664946635563,6.125973095975127,-2.3835164112009726,-34.24227395543317,51.35878781787072,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2024-07-02,1.2300000190734863,1.2300000190734863,1.190000057220459,1.2100000381469727,161785,0.0,0.0,1.177999997138977,1.1894494712352752,1.7900664955377579,2.7164720785835814,-0.9625860007661928,-33.55277727389954,50.2232502789147,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2024-07-03,1.2200000286102295,1.2200000286102295,1.1799999475479126,1.190000057220459,42300,0.0,0.0,1.1820000052452087,1.1876494735479355,1.7749414950609208,0.6768233451564751,-0.47568482355739555,-33.08796504826926,49.05521332509584,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2024-07-04,1.2200000286102295,1.309999942779541,1.1699999570846558,1.2899999618530273,418895,0.0,0.0,1.1860000014305114,1.1906494736671447,1.7601498275995255,8.768967984576292,-0.39049882769553484,-32.355220277415796,54.72497906292542,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2024-07-05,1.2699999809265137,1.4800000190734863,1.2100000381469727,1.3600000143051147,557382,0.0,0.0,1.2040000081062316,1.1956994742155076,1.74681649406751,12.956811058851661,0.6941990081721819,-31.549794825254445,58.22942439897127,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2024-07-08,1.3700000047683716,1.649999976158142,1.3600000143051147,1.6299999952316284,836889,0.0,0.0,1.2610000133514405,1.2074494749307632,1.7351081599791844,29.262488340461868,4.435012771341676,-30.41070852060032,68.3920692154072,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2024-07-09,1.5499999523162842,1.6399999856948853,1.4900000095367432,1.559999942779541,672339,0.0,0.0,1.2980000019073485,1.2182994723320006,1.723774825533231,20.18489526095502,6.541948953059104,-29.32374610151689,64.04177187308662,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2024-07-10,1.559999942779541,1.6299999952316284,1.5199999809265137,1.600000023841858,222176,0.0,0.0,1.3450000047683717,1.2307994723320008,1.7146081586678823,18.959109157579586,9.278565274324876,-28.216865987139787,65.39628468772028,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2024-07-11,1.600000023841858,1.690000057220459,1.5,1.6200000047683716,1684977,0.0,0.0,1.390000009536743,1.2418994724750518,1.7061081578334172,16.54676213335297,11.925324097813915,-27.208631716986975,66.08420825506633,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2024-07-12,1.659999966621399,1.8200000524520874,1.649999976158142,1.75,1242388,0.0,0.0,1.444000005722046,1.2564994722604752,1.697441491484642,21.191135253835707,14.922452225487397,-25.97686114285468,70.22738011757286,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2024-07-15,1.75,1.909999966621399,1.7200000286102295,1.8799999952316284,849781,0.0,0.0,1.50900000333786,1.2747494727373123,1.690649825334549,24.585817831221213,18.37620141136703,-24.600029312098233,73.68881439691137,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2024-07-16,1.8799999952316284,2.0399999618530273,1.8600000143051147,2.0199999809265137,369458,0.0,0.0,1.5899999976158141,1.296749472618103,1.684066492319107,27.044024148143357,22.61427756015555,-22.998914916217743,76.81500455065945,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2024-07-17,2.0799999237060547,2.1600000858306885,1.9299999475479126,2.119999885559082,345913,0.0,0.0,1.6829999804496765,1.3202494710683823,1.6793998241424561,25.965532393686935,27.47590643514869,-21.38563717293856,78.75658579346648,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2024-07-18,2.119999885559082,2.4000000953674316,2.059999942779541,2.4000000953674316,740451,0.0,0.0,1.7939999938011169,1.3503494739532471,1.6771914919217428,33.77926999221027,32.85449644002528,-19.487459812594018,83.03943136986409,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2024-07-19,2.4000000953674316,2.680000066757202,2.2799999713897705,2.5999999046325684,2020902,0.0,0.0,1.9179999828338623,1.3908888459205628,1.6767331580320994,35.55786902516261,37.897430729946635,-17.047692457338783,85.31657931879612,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2024-07-22,2.5999999046325684,2.8399999141693115,2.5199999809265137,2.8399999141693115,565078,0.0,0.0,2.0389999747276306,1.4341478943824768,1.6787748237450917,39.283960243730675,42.17501435621424,-14.571753513487257,87.48757384230177,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2024-07-23,2.880000114440918,2.9600000381469727,2.5,2.799999952316284,1158339,0.0,0.0,2.1629999756813048,1.4676999419927597,1.6800248225529988,29.449837438594344,47.37344560663443,-12.638199014082785,85.22586900886789,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2024-07-24,2.7799999713897705,2.859999895095825,2.5,2.759999990463257,630382,0.0,0.0,2.2789999723434446,1.4982270926237107,1.6833998223145803,21.105749186350828,52.11311980431728,-10.999925700138634,82.91742139123811,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2024-07-25,2.7200000286102295,2.740000009536743,2.5199999809265137,2.619999885559082,833521,0.0,0.0,2.378999960422516,1.5313289135694503,1.6853998204072316,10.130303873303294,55.3552564273855,-9.141504880459413,75.23622210129876,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2024-07-26,2.5799999237060547,2.619999885559082,2.1600000858306885,2.5399999618530273,1490199,0.0,0.0,2.457999956607819,1.5624307364225387,1.6877331535021465,3.336045837786478,57.31897096672868,-7.424302640473574,71.17853826052098,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2024-07-29,2.5999999046325684,2.799999952316284,2.440000057220459,2.5799999237060547,497257,0.0,0.0,2.5279999494552614,1.5959499835968018,1.690233153104782,2.056961047882867,58.400950871774384,-5.578116210464329,71.99191059661473,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2024-07-30,2.880000114440918,3.299999952316284,2.880000114440918,3.0799999237060547,2004294,0.0,0.0,2.6339999437332153,1.640499982237816,1.6977748195330302,16.932421772975275,60.56080294131794,-3.373523781614788,79.70280208092149,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2024-07-31,3.119999885559082,3.5399999618530273,3.0999999046325684,3.4600000381469727,1217761,0.0,0.0,2.7679999589920046,1.694999983906746,1.7095664858818054,25.00000323002053,63.30383393940444,-0.8520582320345313,83.43532464928339,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2024-08-01,3.5,3.9600000381469727,3.5,3.9000000953674316,1246594,0.0,0.0,2.9179999589920045,1.7632499873638152,1.7244831542174022,33.653192260998175,65.48986133013521,2.248026201450837,86.52520817639197,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2024-08-02,3.8399999141693115,4.119999885559082,3.4600000381469727,3.880000114440918,1147270,0.0,0.0,3.0459999799728394,1.8292499899864196,1.7386914889017742,27.380175310293836,66.5163316466905,5.208428387824327,85.74229104521359,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2024-08-05,3.4000000953674316,3.7200000286102295,3.1600000858306885,3.640000104904175,1178728,0.0,0.0,3.125999999046326,1.889499992132187,1.751233156522115,16.442741715120253,65.44059338782125,7.895398456517616,76.76578737446698,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2024-08-06,3.5,3.9000000953674316,3.440000057220459,3.740000009536743,789460,0.0,0.0,3.2200000047683717,1.9529999911785125,1.7646498223145803,16.149068447152914,64.87455296020275,10.673515304973375,77.80828713482006,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2024-08-07,3.740000009536743,4.0,3.5,3.9000000953674316,821707,0.0,0.0,3.334000015258789,2.0209999948740007,1.7794414897759756,16.97660700414571,64.96783887753782,13.574961946539549,79.40087053504081,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2024-08-08,3.880000114440918,3.9600000381469727,3.619999885559082,3.9000000953674316,687374,0.0,0.0,3.462000036239624,2.089749997854233,1.7943164904912312,12.65164802261404,65.66575139583324,16.46496083208379,79.40087053504081,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2024-08-09,3.9200000762939453,4.159999847412109,3.5999999046325684,3.700000047683716,950788,0.0,0.0,3.578000044822693,2.155750000476837,1.8076498250166575,3.4097261412155335,65.97472081787146,19.257058012160723,71.91862452658864,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2024-08-12,3.700000047683716,3.859999895095825,3.4000000953674316,3.859999895095825,954362,0.0,0.0,3.70600004196167,2.2254999965429305,1.8224831581115724,4.155419627373762,66.52437868876808,22.11361112653341,74.02724711890168,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2024-08-13,3.859999895095825,3.859999895095825,3.5199999809265137,3.5799999237060547,243411,0.0,0.0,3.75600004196167,2.2894999951124193,1.8345664898554483,-4.685839091835967,64.05328892683585,24.797875016937475,64.8499789909257,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2024-08-14,3.5999999046325684,3.640000104904175,2.9600000381469727,3.0799999237060547,1357244,0.0,0.0,3.718000030517578,2.337749993801117,1.8427331566810607,-17.15976604558307,59.041815436911314,26.863186095355722,52.365654278421275,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2024-08-15,3.299999952316284,3.7200000286102295,3.299999952316284,3.380000114440918,1097536,0.0,0.0,3.6660000324249267,2.39099999666214,1.8530248244603476,-7.801416133508053,53.32497020253868,29.03227010779338,57.63545262489328,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2024-08-16,3.4200000762939453,3.700000047683716,3.240000009536743,3.359999895095825,931336,0.0,0.0,3.6140000104904173,2.4454999953508376,1.8631081561247507,-7.028226747573376,47.78164045639034,31.259153544658247,57.18127520372035,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2024-08-19,3.259999990463257,3.5199999809265137,3.240000009536743,3.5,440791,0.0,0.0,3.6,2.5064999967813493,1.8735664904117584,-2.77777777777778,43.626571100053376,33.78228152610103,59.5822429543252,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2024-08-20,3.4800000190734863,3.5999999046325684,3.380000114440918,3.5999999046325684,196123,0.0,0.0,3.5859999895095824,2.5667499929666517,1.8860664904117583,0.3904047731160351,39.70974965757693,36.09011166972642,61.2534916364507,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2024-08-21,3.640000104904175,3.940000057220459,3.5399999618530273,3.619999885559082,622811,0.0,0.0,3.5579999685287476,2.6289999902248384,1.8985664904117585,1.7425496789976582,35.33662920342798,38.472895392495026,61.59552258726694,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2024-08-22,3.640000104904175,3.8399999141693115,3.5199999809265137,3.799999952316284,396555,0.0,0.0,3.547999954223633,2.694749990105629,1.9114414890607199,7.10259304802594,31.66341839691623,40.979988429037704,64.62236236556353,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2024-08-23,3.799999952316284,4.0,3.700000047683716,4.0,830630,0.0,0.0,3.5779999494552612,2.764499989151955,1.9271081566810608,11.794300070042956,29.42665811161235,43.45328670670369,67.67123192972457,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2024-08-26,4.099999904632568,4.400000095367432,4.079999923706055,4.320000171661377,844471,0.0,0.0,3.6239999771118163,2.841749992966652,1.9455664912859598,19.20530350290579,27.527051502814725,46.062856535339606,71.85121451599947,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2024-08-27,4.320000171661377,4.619999885559082,4.039999961853027,4.420000076293945,957423,0.0,0.0,3.7079999923706053,2.921999993920326,1.9651914914449056,19.201728300655763,26.899383986504933,48.68779997474586,73.0249795229006,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2024-08-28,4.420000076293945,4.599999904632568,4.300000190734863,4.5,681535,0.0,0.0,3.85,3.0047499924898147,1.985816490650177,16.88311688311688,28.130460425088117,51.31055697427652,73.9604490760079,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2024-08-29,4.5,4.5,3.799999952316284,3.880000114440918,965390,0.0,0.0,3.9,3.069499996304512,2.001108157634735,-0.5128175784379985,27.056524016789645,53.390009660077176,57.358698573948345,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2024-08-30,3.880000114440918,4.079999923706055,3.799999952316284,3.9600000381469727,402949,0.0,0.0,3.960000014305115,3.1344999969005585,2.0174748241901397,6.020671145255559e-07,26.335939327510715,55.36749005821265,58.64851556780789,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2024-09-02,4.0,4.179999828338623,3.819999933242798,3.880000114440918,176680,0.0,0.0,3.9980000257492065,3.190749999880791,2.033691491683324,-2.9514735004579182,25.299695240886162,56.89449520387914,56.79831925354107,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2024-09-03,3.9000000953674316,4.0,3.6600000858306885,3.700000047683716,305226,0.0,0.0,4.008000040054322,3.244250002503395,2.0475664913654326,-7.684630471371737,23.541651751917584,58.44418318937943,52.76489727174526,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2024-09-04,3.680000066757202,3.680000066757202,3.4000000953674316,3.5,373052,0.0,0.0,3.996000051498413,3.2917500019073485,2.0607998251914976,-12.412413541196624,21.394396572734838,59.731671250577,48.632457710258365,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2024-09-05,3.4800000190734863,3.700000047683716,3.240000009536743,3.640000104904175,507759,0.0,0.0,3.980000066757202,3.3422500044107437,2.0747331589460374,-8.542712466084206,19.081458942473603,61.09300562336429,51.496114017419515,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2024-09-06,3.5199999809265137,3.619999885559082,3.359999895095825,3.5199999809265137,184933,0.0,0.0,3.9320000648498534,3.3865000039339064,2.088066492478053,-10.478130140597349,16.108077964927517,62.183532762642656,48.9758165192312,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2024-09-09,3.5,3.559999942779541,3.200000047683716,3.4800000190734863,316191,0.0,0.0,3.8480000495910645,3.426500004529953,2.10164982577165,-9.563410233237557,12.301183262917654,63.038578668635544,48.130230377235165,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2024-09-10,3.4800000190734863,3.9200000762939453,3.4200000762939453,3.740000009536743,470276,0.0,0.0,3.7800000429153444,3.4695000052452087,2.1178164929151535,-1.0582019292187896,8.94941741463381,63.82439256904059,53.72314794728388,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2024-09-11,3.759999990463257,4.0,3.6600000858306885,3.759999990463257,267036,0.0,0.0,3.70600004196167,3.510500007867813,2.1333998262882234,1.4570951940141732,5.569008222637742,64.54955909392403,54.13284873596011,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2024-09-12,3.759999990463257,4.0,3.700000047683716,3.9600000381469727,402791,0.0,0.0,3.714000034332275,3.5495000064373015,2.1505998263756436,6.623586471208117,4.634456334600361,65.04697726211538,58.12530232983119,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2024-09-13,3.9600000381469727,3.9600000381469727,3.7799999713897705,3.880000114440918,112844,0.0,0.0,3.70600004196167,3.58150001168251,2.1673498272895815,4.6950909473585885,3.476197958203343,65.2478970670563,56.02461625452938,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2024-09-16,3.880000114440918,3.9200000762939453,3.7200000286102295,3.7799999713897705,185932,0.0,0.0,3.696000027656555,3.6050000131130218,2.183683159947395,2.2727257333511326,2.5242722389049894,65.08805303054433,53.425416939947034,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2024-09-17,3.7200000286102295,3.859999895095825,3.640000104904175,3.700000047683716,98355,0.0,0.0,3.696000027656555,3.6275000154972075,2.1988664935032527,0.10822564927568551,1.8883531872282706,64.97136257317031,51.37207427995135,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2024-09-18,3.700000047683716,3.7799999713897705,3.6600000858306885,3.7200000286102295,166408,0.0,0.0,3.718000030517578,3.651500016450882,2.2140331606070203,0.05379230974274256,1.8211697594713887,64.92526315413235,51.870101576838024,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2024-09-19,3.7799999713897705,3.9800000190734863,3.7200000286102295,3.859999895095825,313385,0.0,0.0,3.740000009536743,3.6825000166893007,2.2306164930264156,3.2085530816334376,1.5614390383394214,65.08889036739008,55.31968278738505,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2024-09-20,3.8399999141693115,3.9000000953674316,3.7200000286102295,3.819999933242798,105763,0.0,0.0,3.7700000047683715,3.714500015974045,2.2470664928356805,1.3262580480420543,1.494144260483277,65.30441034197167,54.1260401518306,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2024-09-23,3.819999933242798,4.039999961853027,3.4000000953674316,3.799999952316284,400175,0.0,0.0,3.8019999980926515,3.7450000166893007,2.263483158747355,-0.05260509672200756,1.5220288691411177,65.45296580699274,53.5044003256099,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2024-09-24,3.7799999713897705,3.7799999713897705,3.4000000953674316,3.5,212416,0.0,0.0,3.777999997138977,3.755500018596649,2.277233158548673,-7.358390612744898,0.5991207144431235,64.9150419445897,45.13129331379286,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2024-09-25,3.559999942779541,3.5799999237060547,3.4000000953674316,3.4800000190734863,202846,0.0,0.0,3.75,3.756000018119812,2.29081649184227,-7.199999491373697,-0.159744890598153,63.95900900378295,44.62985707634014,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2024-09-26,3.4800000190734863,3.5,3.359999895095825,3.4200000762939453,252258,0.0,0.0,3.696000003814697,3.744000017642975,2.304333159327507,-7.467530498806499,-1.2820516453548512,62.476506597492964,43.08334508938249,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2024-09-27,3.440000057220459,3.5799999237060547,3.3399999141693115,3.5199999809265137,162553,0.0,0.0,3.6599999904632567,3.7350000143051147,2.319133159518242,-3.8251368825556438,-2.008032759159481,61.051554930161636,46.41604343318923,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2024-09-30,3.5199999809265137,3.740000009536743,3.440000057220459,3.5999999046325684,129603,0.0,0.0,3.6419999837875365,3.7340000092983248,2.3345831582943597,-1.1532146991195136,-2.463846418899084,59.94290012896244,48.98935359513136,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2024-10-01,3.640000104904175,3.700000047683716,3.440000057220459,3.640000104904175,201591,0.0,0.0,3.6359999895095827,3.7315000116825106,2.3505831589301427,0.11001417508616758,-2.559293095911515,58.74784082860893,50.275195910961656,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2024-10-02,3.619999885559082,3.619999885559082,3.4800000190734863,3.5199999809265137,64640,0.0,0.0,3.6159999847412108,3.7220000088214875,2.364749825000763,-2.6548673733351134,-2.847931859995884,57.395085495789665,46.48917556257497,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2024-10-03,3.5199999809265137,3.5799999237060547,3.4200000762939453,3.559999942779541,121482,0.0,0.0,3.5859999895095824,3.7135000050067903,2.3787498245636622,-0.7250431345817475,-3.433419020474049,56.11141477174731,47.8976502544917,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2024-10-04,3.5799999237060547,3.5799999237060547,3.359999895095825,3.4000000953674316,89898,0.0,0.0,3.544000005722046,3.706000006198883,2.391249825557073,-4.063202881549549,-4.371289805878738,54.98171569486772,43.01988066584107,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2024-10-07,3.4200000762939453,3.4200000762939453,3.259999990463257,3.380000114440918,88719,0.0,0.0,3.502000021934509,3.6940000116825105,2.4044331600268682,-3.4837209231711608,-5.1976174645584505,53.632884169723894,42.43810209183753,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2024-10-08,3.380000114440918,3.4000000953674316,3.119999885559082,3.240000009536743,180224,0.0,0.0,3.4760000228881838,3.6855000138282774,2.4166831602652867,-6.789413457924833,-5.684438750618197,52.5024080286846,38.511946930178254,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2024-10-09,3.2200000286102295,3.380000114440918,3.140000104904175,3.359999895095825,88923,0.0,0.0,3.4640000104904174,3.6925000131130217,2.4300998260577518,-3.002312790982594,-6.188219412624014,51.9484909022527,43.34977365454918,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2024-10-10,3.359999895095825,3.5399999618530273,3.200000047683716,3.5399999618530273,147525,0.0,0.0,3.4759999990463255,3.6965000092983247,2.445149826010068,1.8411957084079646,-5.965102385969014,51.17683055562191,49.73794199348105,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2024-10-11,3.5399999618530273,3.5799999237060547,3.440000057220459,3.5,70653,0.0,0.0,3.4740000009536742,3.700000011920929,2.458716492851575,0.7484167829357603,-6.108108384840849,50.48502024036679,48.43096067282907,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2024-10-14,3.5,3.559999942779541,3.4000000953674316,3.5199999809265137,83650,0.0,0.0,3.4660000085830687,3.700500011444092,2.4727664927641553,1.5579911197265306,-6.3369815467048545,49.650200383762396,49.150448390583904,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2024-10-15,3.5,3.5399999618530273,3.380000114440918,3.5199999809265137,84443,0.0,0.0,3.4539999961853027,3.6985000133514405,2.4875164926052094,1.910827585816538,-6.6107885976342375,48.68243182894245,49.150448390583904,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2024-10-16,3.4600000381469727,3.6600000858306885,3.359999895095825,3.5999999046325684,180354,0.0,0.0,3.4619999885559083,3.6980000138282776,2.50334982474645,3.986132771023592,-6.3818286746855675,47.72206334377685,52.24155430275457,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2024-10-17,3.5999999046325684,3.5999999046325684,3.4800000190734863,3.5399999618530273,55224,0.0,0.0,3.459999990463257,3.6915000140666963,2.5232164909442267,2.312137907811358,-6.271164099181732,46.301358893119776,49.79659114783205,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2024-10-18,3.5399999618530273,3.859999895095825,3.5399999618530273,3.6600000858306885,62794,0.0,0.0,3.4859999895095823,3.683000016212463,2.54401649137338,4.991396926125201,-5.3489010544581115,44.77107474347411,54.393813695016505,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2024-10-21,3.700000047683716,3.700000047683716,3.5399999618530273,3.640000104904175,34078,0.0,0.0,3.511999988555908,3.6660000145435334,2.565016492207845,3.644650249583252,-4.2007644674491464,42.92305822127536,53.514255899449516,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2024-10-22,3.640000104904175,3.640000104904175,3.5,3.619999885559082,35216,0.0,0.0,3.549999976158142,3.646000009775162,2.585816491643588,1.9718284470721288,-2.6330234053658153,40.99995191297213,52.59829610932546,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2024-10-23,3.619999885559082,3.700000047683716,3.559999942779541,3.640000104904175,72858,0.0,0.0,3.577999997138977,3.624500012397766,2.6056331594785056,1.7328146398763038,-1.2829359939228562,39.10246725303334,53.456228710243444,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2024-10-24,3.640000104904175,3.680000066757202,3.5399999618530273,3.6600000858306885,72137,0.0,0.0,3.5900000095367433,3.6190000116825103,2.626383160551389,1.9498628442337553,-0.8013263899461729,37.79406089866677,54.34607872074143,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2024-10-25,3.6600000858306885,3.680000066757202,3.559999942779541,3.640000104904175,47223,0.0,0.0,3.6040000200271605,3.6110000133514406,2.6470664948225022,0.9988924716138884,-0.19385193293819206,36.41516072279758,53.24970867989791,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2024-10-28,3.680000066757202,3.799999952316284,3.640000104904175,3.759999990463257,137698,0.0,0.0,3.628000020980835,3.608000010251999,2.668733161687851,3.638367384759152,0.5543240208427596,35.195232781163654,58.64102316979715,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2024-10-29,3.759999990463257,3.7799999713897705,3.6600000858306885,3.700000047683716,56517,0.0,0.0,3.646000027656555,3.608000010251999,2.6901831616957983,1.4810756889069152,1.0532155570005717,34.11726240891496,55.212534519197014,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2024-10-30,3.700000047683716,3.700000047683716,3.559999942779541,3.640000104904175,42882,0.0,0.0,3.650000047683716,3.611500012874603,2.7113498290379843,-0.27397103147675683,1.066040001989879,33.19933762129107,51.94210066474625,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2024-10-31,3.5799999237060547,3.640000104904175,3.440000057220459,3.640000104904175,138519,0.0,0.0,3.6600000619888307,3.611500012874603,2.731883163253466,-0.5464469056262242,1.3429336547509396,32.19818700348736,51.942100664746235,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2024-11-01,3.640000104904175,3.700000047683716,3.5999999046325684,3.680000066757202,58364,0.0,0.0,3.662000060081482,3.6155000150203707,2.752833163738251,0.49153485473508435,1.2861304070786812,31.33741857827114,54.04666788447762,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2024-11-04,3.619999885559082,3.740000009536743,3.5399999618530273,3.640000104904175,116064,0.0,0.0,3.662000060081482,3.619500017166138,2.7735831648111344,-0.6007633756515454,1.1741965109484724,30.499062118896497,51.61256920986976,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2024-11-05,3.559999942779541,3.5999999046325684,3.4600000381469727,3.559999942779541,66269,0.0,0.0,3.6560000658035277,3.6150000154972077,2.793749831120173,-2.625823886654866,1.13416459558938,29.39598153095006,47.0487031861533,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2024-11-06,3.559999942779541,3.5799999237060547,3.380000114440918,3.440000057220459,98566,0.0,0.0,3.636000061035156,3.6070000171661376,2.8125831653674442,-5.390539068332598,0.8039934497090084,28.24509730345728,41.16820656583878,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2024-11-07,3.4600000381469727,3.5,3.3399999141693115,3.5,73987,0.0,0.0,3.6200000524520872,3.5955000162124633,2.8317831655343375,-3.3149185279929076,0.6814083195425076,26.969467859450948,44.87797017567199,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2024-11-08,3.4000000953674316,3.4800000190734863,3.3399999141693115,3.4000000953674316,179660,0.0,0.0,3.596000051498413,3.583500015735626,2.8519629577795667,-5.4504992581774445,0.3488219815235889,25.650300119101377,40.315126320797255,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2024-11-11,3.3399999141693115,3.8399999141693115,3.3399999141693115,3.680000066757202,354143,0.0,0.0,3.5880000591278076,3.581000018119812,2.8733826418717703,2.5641027344843033,0.19547726815346747,24.626632246483105,54.31981206334621,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2024-11-12,3.680000066757202,3.740000009536743,3.5999999046325684,3.740000009536743,134336,0.0,0.0,3.59200005531311,3.5820000171661377,2.892399991552035,4.120265922733457,0.27917470963285773,23.84179323842654,56.666269596289204,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2024-11-13,3.819999933242798,4.0,3.799999952316284,3.859999895095825,220240,0.0,0.0,3.6140000343322756,3.5855000138282778,2.9117423743009567,6.806858285185398,0.7948687880095143,23.13932872200189,60.98298606654772,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2024-11-14,3.859999895095825,4.300000190734863,3.759999990463257,4.119999885559082,579181,0.0,0.0,3.6620000123977663,3.592000013589859,2.9352763146162033,12.506823364575343,1.9487750151189147,22.373488168848066,68.34156665249043,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2024-11-15,4.179999828338623,4.179999828338623,3.799999952316284,3.9200000762939453,436541,0.0,0.0,3.6860000133514403,3.594500017166138,2.9571435898542404,6.348346774142953,2.545555591829987,21.55311055907546,59.10693836923096,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2024-11-18,3.9800000190734863,3.9800000190734863,3.559999942779541,3.7200000286102295,264336,0.0,0.0,3.694000005722046,3.592500019073486,2.9778166731198628,0.7038446899813016,2.8253301631084424,20.642081545927365,51.59839215115028,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2024-11-19,3.740000009536743,3.799999952316284,3.5199999809265137,3.619999885559082,175929,0.0,0.0,3.7,3.5955000162124633,2.997166672348976,-2.1621652551599495,2.9064103272517365,19.96329898445568,48.294895789694934,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2024-11-20,3.619999885559082,3.7200000286102295,3.5799999237060547,3.700000047683716,176318,0.0,0.0,3.7259999990463255,3.601000016927719,3.0173333396514255,-0.697797943351165,3.4712574710080975,19.343791738426926,50.99778535402576,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2024-11-21,3.740000009536743,3.819999933242798,3.640000104904175,3.700000047683716,54689,0.0,0.0,3.7460000038146974,3.6080000162124635,3.0384166737397513,-1.2279753359353465,3.824833342076892,18.746057688383345,50.99778535402577,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2024-11-22,3.640000104904175,3.7200000286102295,3.5999999046325684,3.7200000286102295,86453,0.0,0.0,3.777999997138977,3.6130000174045565,3.0590833405653637,-1.5352029796895201,4.566841376683701,18.107276434542015,51.72940542815325,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2024-11-25,3.680000066757202,3.8399999141693115,3.619999885559082,3.7799999713897705,199519,0.0,0.0,3.787999987602234,3.6175000190734865,3.080333340167999,-0.21119367050281618,4.713198828742945,17.438589255933927,53.95066448036252,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2024-11-26,3.7799999713897705,3.859999895095825,3.740000009536743,3.819999933242798,240631,0.0,0.0,3.7959999799728394,3.622000014781952,3.1021666725476584,0.6322432401627707,4.803974723378416,16.75710550417911,55.42337428327996,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2024-11-27,3.819999933242798,3.9000000953674316,3.680000066757202,3.819999933242798,255865,0.0,0.0,3.7919999837875364,3.629500013589859,3.124166672428449,0.7383952946986677,4.4771998784745035,16.17498021539961,55.42337428327996,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2024-11-28,3.759999990463257,3.819999933242798,3.619999885559082,3.819999933242798,160569,0.0,0.0,3.761999988555908,3.6360000133514405,3.146416672070821,1.5417316550591953,3.4653458399833337,15.560028829824343,55.423374283279976,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2024-11-29,3.819999933242798,3.819999933242798,3.5,3.819999933242798,297425,0.0,0.0,3.7519999742507935,3.6465000092983244,3.1694166719913484,1.8123656572141305,2.8931842776210446,15.052717477100416,55.42337428327996,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2024-12-02,3.7799999713897705,4.400000095367432,3.5999999046325684,3.940000057220459,465056,0.0,0.0,3.7739999771118162,3.660500007867813,3.193333338697751,4.398518312543288,3.10066846059414,14.629436379497212,60.51843142945716,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2024-12-03,3.940000057220459,4.0,3.759999990463257,3.9000000953674316,445164,0.0,0.0,3.8019999980926515,3.6770000100135802,3.2173333396514256,2.577593301524034,3.3995101370317826,14.287194450667522,58.13320980867428,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2024-12-04,3.9200000762939453,4.0,3.7799999713897705,3.880000114440918,449104,0.0,0.0,3.8200000047683718,3.6900000154972075,3.2400833408037824,1.5706834973206856,3.5230349248019586,13.885959938975281,56.92511864865657,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2024-12-05,3.819999933242798,3.9200000762939453,3.7200000286102295,3.759999990463257,143219,0.0,0.0,3.8259999990463256,3.6955000162124634,3.261000007390976,-1.7250394302017777,3.531321397952862,13.324133941634585,50.186113824050224,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2024-12-06,3.7799999713897705,3.7799999713897705,3.5,3.7200000286102295,183750,0.0,0.0,3.8259999990463256,3.7010000169277193,3.282166674733162,-2.7705167397417094,3.377465051253134,12.760879738948914,48.14031323025413,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2024-12-09,3.9000000953674316,4.159999847412109,3.299999952316284,3.7799999713897705,1143784,0.0,0.0,3.8259999990463256,3.7075000166893006,3.3048333416382474,-1.2023007754318118,3.196223380272357,12.184174916712935,51.34429090809453,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2024-12-10,3.819999933242798,3.8399999141693115,3.440000057220459,3.7799999713897705,710247,0.0,0.0,3.822000002861023,3.714000016450882,3.3264166742563246,-1.0989019215021636,2.9079156147486085,11.651677470057416,51.34429090809453,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2024-12-11,3.700000047683716,3.700000047683716,3.5999999046325684,3.6600000858306885,179256,0.0,0.0,3.806000018119812,3.715500020980835,3.3475000083446504,-3.836046547399869,2.435742070459912,10.993278916171285,44.908686925267844,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2024-12-12,3.680000066757202,3.680000066757202,3.5399999618530273,3.5799999237060547,119119,0.0,0.0,3.782000017166138,3.7165000200271607,3.3675833413998286,-5.341091817642094,1.762410783963845,10.361040641158871,41.201026852878236,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2024-12-13,3.640000104904175,3.640000104904175,3.3399999141693115,3.5,380652,0.0,0.0,3.750000023841858,3.7125000178813936,3.3866666744152707,-6.666667260064013,1.0101011657870451,9.621063269309788,37.83692756033357,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2024-12-16,3.5,3.559999942779541,3.3399999141693115,3.5,189195,0.0,0.0,3.706000018119812,3.709000015258789,3.4055833409229916,-5.558554158462285,-0.08088425793030955,8.909389198901954,37.83692756033357,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2024-12-17,3.4600000381469727,3.559999942779541,3.380000114440918,3.5,155584,0.0,0.0,3.666000008583069,3.706000018119812,3.4246666739384333,-4.528096240982521,-1.079331066950087,8.214911726221803,37.836927560333564,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2024-12-18,3.559999942779541,3.559999942779541,3.4200000762939453,3.5,278140,0.0,0.0,3.627999997138977,3.7025000154972076,3.443916673461596,-3.528114587649319,-2.012154437445044,7.508408784342069,37.836927560333564,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2024-12-19,3.5,3.5199999809265137,3.380000114440918,3.4800000190734863,382636,0.0,0.0,3.6,3.6980000138282776,3.4621666739384334,-3.333332803514271,-2.650081488962057,6.81172693576791,36.82583229031452,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2024-12-20,3.440000057220459,3.559999942779541,3.319999933242798,3.5,263398,0.0,0.0,3.577999997138977,3.6945000112056734,3.480000007152557,-2.1799887423517847,-3.1533364112422233,6.163793207248487,38.59300400249977,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2024-12-23,3.5199999809265137,3.5199999809265137,3.299999952316284,3.299999952316284,283690,0.0,0.0,3.5299999952316283,3.683000010251999,3.4939166734615963,-6.515581961077374,-4.154222497813736,5.411787242283273,29.658450074856916,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2024-12-27,3.359999895095825,3.4000000953674316,3.119999885559082,3.319999933242798,472883,0.0,0.0,3.483999991416931,3.673500007390976,3.50858334004879,-4.707234746789851,-5.158568547509907,4.700377655555217,31.369511289739407,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2024-12-30,3.299999952316284,3.559999942779541,3.259999990463257,3.4600000381469727,162722,0.0,0.0,3.4639999866485596,3.669000005722046,3.524083340167999,-0.11547195487887077,-5.587354013458039,4.112180432916164,42.00438288568482,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2025-01-02,3.4600000381469727,3.5,3.2799999713897705,3.4200000762939453,170537,0.0,0.0,3.4480000019073485,3.66350000500679,3.5390833407640456,-0.8120628073641031,-5.882353017740536,3.515505351616963,40.092781881849696,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2025-01-03,3.359999895095825,3.4200000762939453,3.180000066757202,3.299999952316284,329243,0.0,0.0,3.427999997138977,3.654000002145767,3.552000007033348,-3.7339569699393858,-6.185002870116977,2.871621478334677,34.95352400668979,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2025-01-07,3.2799999713897705,3.2799999713897705,3.0999999046325684,3.259999990463257,287537,0.0,0.0,3.403999996185303,3.6444999992847444,3.563500006993612,-4.230317446633956,-6.5989848579130514,2.273045941691164,33.415900689881795,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2025-01-08,3.200000047683716,3.380000114440918,3.200000047683716,3.3399999141693115,90310,0.0,0.0,3.387999987602234,3.6389999985694885,3.574500006437302,-1.4167672257547206,-6.897499617090522,1.8044479512107696,39.17864994598033,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2025-01-09,3.359999895095825,3.359999895095825,3.2799999713897705,3.359999895095825,42149,0.0,0.0,3.3739999771118163,3.6369999945163727,3.5848333398501078,-0.41494019297461165,-7.231235023400889,1.4552044605913577,40.563607077994384,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2025-01-10,3.4000000953674316,3.4000000953674316,3.240000009536743,3.2799999713897705,73592,0.0,0.0,3.353999972343445,3.6314999938011168,3.592166672150294,-2.206320857598887,-7.64147107066936,1.0949748505761219,36.94014632852216,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2025-01-13,3.259999990463257,3.3399999141693115,3.140000104904175,3.299999952316284,151559,0.0,0.0,3.3339999675750733,3.6289999902248384,3.5980000058809916,-1.0197965083820462,-8.128961792350076,0.8615893355524425,38.42110712620124,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2025-01-14,3.2799999713897705,3.3399999141693115,3.180000066757202,3.299999952316284,103351,0.0,0.0,3.3339999675750733,3.6194999873638154,3.601833339532216,-1.0197965083820462,-7.887830385010716,0.49049042990683317,38.421107126201235,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2025-01-15,3.319999933242798,3.4000000953674316,3.180000066757202,3.319999933242798,149824,0.0,0.0,3.3339999675750733,3.6089999854564665,3.606166672706604,-0.4199170506428697,-7.619839816835332,0.07856854679808174,40.05386269880989,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2025-01-16,3.319999933242798,3.319999933242798,3.2200000286102295,3.2799999713897705,81752,0.0,0.0,3.315999960899353,3.5944999873638155,3.6105000058809917,-1.0856450522942354,-7.7479490177634585,-0.44315243016519856,37.89000526930961,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2025-01-17,3.240000009536743,3.240000009536743,3.059999942779541,3.119999885559082,211006,0.0,0.0,3.2859999418258665,3.569499987363815,3.614666672547658,-5.051736433523688,-7.942290139838944,-1.2495394257752968,30.7369667019494,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2025-01-20,3.0999999046325684,3.4200000762939453,3.0399999618530273,3.180000066757202,199391,0.0,0.0,3.2739999532699584,3.5509999871253966,3.620000006755193,-2.8711022557856913,-7.800620525478376,-1.9060778867689823,35.64350627009344,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2025-01-21,3.2200000286102295,3.2200000286102295,3.0399999618530273,3.0999999046325684,244912,0.0,0.0,3.2579999446868895,3.535499984025955,3.6243333399295805,-4.849602293946807,-7.848961691213755,-2.451026094232033,32.35266560063263,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2025-01-22,3.119999885559082,3.200000047683716,3.0,3.0799999237060547,275819,0.0,0.0,3.231999945640564,3.5219999849796295,3.6243333399295805,-4.702971054796349,-8.233959130489396,-2.823508362835613,31.56797833583788,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2025-01-23,3.0999999046325684,3.240000009536743,3.0,3.200000047683716,208587,0.0,0.0,3.215999960899353,3.5094999849796293,3.6221666733423867,-0.49750974534100545,-8.363015396393566,-3.110477747805934,40.83957659940698,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2025-01-24,3.2200000286102295,3.380000114440918,3.180000066757202,3.2799999713897705,209386,0.0,0.0,3.215999960899353,3.498999983072281,3.617000005642573,1.9900501016337047,-8.088025822864994,-3.262372750517291,46.08408490193598,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2025-01-27,3.4600000381469727,3.4600000381469727,3.119999885559082,3.180000066757202,128583,0.0,0.0,3.203999972343445,3.4854999840259553,3.6111666719118753,-0.7490607301313096,-8.076316539165825,-3.4799470449085588,41.170945962291874,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2025-01-28,3.140000104904175,3.140000104904175,2.8399999141693115,2.9600000381469727,724491,0.0,0.0,3.1699999809265136,3.4649999856948854,3.6055000046888988,-6.624603913031037,-8.51370868647237,-3.896824817952993,32.86865658861471,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2025-01-29,2.9600000381469727,3.0,2.859999895095825,2.880000114440918,237638,0.0,0.0,3.125999999046326,3.4414999902248384,3.5983333388964334,-7.869478076790054,-9.167513935047273,-4.3584997247557355,30.46301242879663,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2025-01-30,2.9000000953674316,2.9600000381469727,2.740000009536743,2.819999933242798,222558,0.0,0.0,3.0799999952316286,3.416499990224838,3.589333337545395,-8.44156046725181,-9.849260821191004,-4.815193548971157,28.76270728923045,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2025-01-31,2.819999933242798,2.9600000381469727,2.799999952316284,2.9200000762939453,174662,0.0,0.0,3.060000014305115,3.393999993801117,3.5811666707197825,-4.575161351525736,-9.840895112139881,-5.226416252808661,35.24949822081544,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2025-02-03,2.9000000953674316,2.9200000762939453,2.6600000858306885,2.8399999141693115,401079,0.0,0.0,3.0259999990463258,3.36949999332428,3.5740000029404957,-6.146731161124721,-10.194390709556409,-5.72188051057538,32.68530928071608,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2025-02-04,2.759999990463257,2.859999895095825,2.7200000286102295,2.7799999713897705,265472,0.0,0.0,2.9940000057220457,3.3404999911785125,3.5650000035762788,-7.147629723556599,-10.372698289821674,-6.2973355448122295,30.871469042057697,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2025-02-05,2.759999990463257,3.0399999618530273,2.7200000286102295,2.9800000190734863,290285,0.0,0.0,2.984000015258789,3.317499989271164,3.560000004371007,-0.13404812884880818,-10.052749814345683,-6.8117981685982905,42.35492454160406,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2025-02-06,2.9600000381469727,2.9800000190734863,2.819999933242798,2.9000000953674316,139829,0.0,0.0,2.9540000200271606,3.292999988794327,3.558500005801519,-1.8280272272724094,-10.294563313718234,-7.461009317812002,39.526480647684494,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2025-02-07,2.940000057220459,2.940000057220459,2.859999895095825,2.9200000762939453,49375,0.0,0.0,2.918000030517578,3.271999990940094,3.554666672150294,0.06854166399760485,-10.81906972502181,-7.95198839387123,40.59453836677655,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2025-02-10,2.859999895095825,2.940000057220459,2.7799999713897705,2.940000057220459,111222,0.0,0.0,2.894000029563904,3.2524999916553496,3.5511666735013327,1.5894964473613642,-11.02228940849246,-8.410381976003048,41.70334996946525,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2025-02-11,2.940000057220459,3.0999999046325684,2.9200000762939453,3.0399999618530273,336071,0.0,0.0,2.9020000219345095,3.233999991416931,3.5473333398501077,4.755339037748366,-10.26592363523664,-8.832926551143245,47.02734693138558,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2025-02-12,3.0799999237060547,3.0799999237060547,2.8399999141693115,3.0,309581,0.0,0.0,2.9140000104904176,3.214499992132187,3.5423333406448365,2.9512693617015087,-9.348265122951425,-9.254728931099736,45.24729964152959,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2025-02-13,3.0,3.0799999237060547,2.9600000381469727,3.0399999618530273,117728,0.0,0.0,2.9360000133514403,3.198999989032745,3.537500007947286,3.542232562283649,-8.221318430226876,-9.568905106828907,47.39176709463345,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2025-02-14,3.0199999809265137,3.119999885559082,3.0199999809265137,3.119999885559082,175958,0.0,0.0,2.955999994277954,3.187499988079071,3.5318333407243094,5.548034221873785,-7.262744930726385,-9.749422450794992,51.48446266121385,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2025-02-17,3.0799999237060547,3.2200000286102295,3.0799999237060547,3.2200000286102295,204666,0.0,0.0,2.9940000057220457,3.1804999887943266,3.5253333409627277,7.548430943762829,-5.863857372405772,-9.781581451081477,56.083617370834,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2025-02-18,3.180000066757202,3.240000009536743,3.0999999046325684,3.2200000286102295,222149,0.0,0.0,3.0380000114440917,3.1734999895095823,3.5161666731039682,5.9907839526184,-4.269733055408964,-9.745461903598837,56.083617370834,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2025-02-19,3.259999990463257,3.4000000953674316,3.2200000286102295,3.2799999713897705,297581,0.0,0.0,3.06800000667572,3.167999988794327,3.506666672229767,6.910037948264527,-3.156565103292967,-9.657795139681577,58.801308974028856,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2025-02-20,3.299999952316284,3.3399999141693115,3.240000009536743,3.3399999141693115,97153,0.0,0.0,3.111999988555908,3.1639999866485597,3.4970000048478442,7.32647578572789,-1.6434892007610942,-9.52244831963543,61.375391053460724,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2025-02-21,3.3399999141693115,3.380000114440918,3.259999990463257,3.299999952316284,91764,0.0,0.0,3.149999976158142,3.1594999849796297,3.4921666701634724,4.7619040410624915,-0.3006807680535201,-9.526082704645656,58.74045718352957,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2025-02-24,3.3399999141693115,3.380000114440918,3.0,3.0999999046325684,396602,0.0,0.0,3.165999960899353,3.1494999825954437,3.4850000023841856,-2.084651202839449,0.5238919953989699,-9.626973301555724,47.71110245014753,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2025-02-25,3.1600000858306885,3.200000047683716,2.940000057220459,3.200000047683716,443303,0.0,0.0,3.1819999694824217,3.1469999849796295,3.479333335161209,0.5656844240706257,1.1121698338050272,-9.551638724094293,52.512295461160804,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2025-02-26,3.200000047683716,3.2799999713897705,3.0999999046325684,3.2200000286102295,126636,0.0,0.0,3.203999972343445,3.1444999873638153,3.4753333350022633,0.4993775407270663,1.8921922473757518,-9.519470961430308,53.43323140879634,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2025-02-27,3.180000066757202,3.200000047683716,3.0399999618530273,3.0799999237060547,124116,0.0,0.0,3.2079999685287475,3.1349999845027923,3.4718333343664805,-3.990026374015089,2.328548146309893,-9.701887084540926,46.617935075298895,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2025-02-28,3.0799999237060547,3.140000104904175,3.0,3.0399999618530273,106424,0.0,0.0,3.199999976158142,3.1254999816417692,3.4668333331743875,-5.000000484287737,2.3836184595732797,-9.845681021535528,44.857483395428666,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2025-03-03,3.0,3.0,2.740000009536743,2.880000114440918,551046,0.0,0.0,3.165999984741211,3.1149999856948853,3.4615000009536745,-9.033476679680739,1.637239142232251,-10.010111661514525,38.581337501750895,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2025-03-04,2.859999895095825,2.880000114440918,2.700000047683716,2.799999952316284,146959,0.0,0.0,3.1239999771118163,3.103499984741211,3.4558333337306975,-10.371319691720194,0.6605443038954841,-10.195322371323092,35.878335344722686,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2025-03-05,2.819999933242798,2.859999895095825,2.759999990463257,2.819999933242798,90625,0.0,0.0,3.077999973297119,3.090499985218048,3.448166666428248,-8.382067650830887,-0.40446568454026177,-10.372662223450064,37.06542042336201,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2025-03-06,2.799999952316284,2.799999952316284,2.619999885559082,2.7200000286102295,190964,0.0,0.0,3.015999984741211,3.074499988555908,3.4395000000794727,-9.814322202537411,-1.9027485455342101,-10.6120078940291,33.70547518238968,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2025-03-07,2.7200000286102295,2.880000114440918,2.640000104904175,2.799999952316284,179700,0.0,0.0,2.965999984741211,3.062499988079071,3.4298333326975503,-5.59676443961312,-3.151020529420112,-10.709947364397827,38.50786604330799,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2025-03-10,2.799999952316284,2.799999952316284,2.7200000286102295,2.799999952316284,137936,0.0,0.0,2.9359999895095825,3.049999988079071,3.420833331346512,-4.6321538719083994,-3.7377048857395985,-10.840438786343123,38.507866043308,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2025-03-11,2.759999990463257,2.7799999713897705,2.680000066757202,2.740000009536743,133489,0.0,0.0,2.8899999856948853,3.0359999895095826,3.4121666649977365,-5.1903106193986845,-4.808959299050635,-11.024276139465872,36.225304397637494,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2025-03-12,2.740000009536743,2.759999990463257,2.619999885559082,2.640000104904175,121478,0.0,0.0,2.83199999332428,3.018999993801117,3.4033333321412402,-6.779657092962429,-6.194104036462482,-11.292850297984659,32.741853036794154,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2025-03-13,2.6600000858306885,2.700000047683716,2.559999942779541,2.619999885559082,94289,0.0,0.0,2.7859999895095826,3.0024999916553496,3.394166664282481,-5.958366998404815,-7.210657876685136,-11.53940602707347,32.077471295392485,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2025-03-14,2.640000104904175,2.680000066757202,2.5799999237060547,2.619999885559082,83737,0.0,0.0,2.743999981880188,2.98999999165535,3.383833330869675,-4.518953977402764,-8.227425099053907,-11.638674269843731,32.0774712953925,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2025-03-17,2.5799999237060547,2.640000104904175,2.5,2.640000104904175,155535,0.0,0.0,2.719999980926514,2.976499992609024,3.3739999989668528,-2.941171933210407,-8.617504193496647,-11.781268716050587,33.63916423739545,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2025-03-18,2.619999885559082,2.740000009536743,2.4800000190734863,2.640000104904175,221157,0.0,0.0,2.7039999961853027,2.964999997615814,3.364333333571752,-2.3668598879961715,-8.802698200350221,-11.869612679906023,33.63916423739545,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2025-03-19,2.5799999237060547,2.740000009536743,2.5,2.740000009536743,167710,0.0,0.0,2.696000003814697,2.9564999997615815,3.3580000003178916,1.632047687677608,-8.811094062840914,-11.956521754565257,41.445960678668655,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2025-03-20,2.7200000286102295,2.740000009536743,2.619999885559082,2.680000066757202,135313,0.0,0.0,2.6920000076293946,2.9435000002384184,3.351333334048589,-0.4457630326219707,-8.544249790679556,-12.169285868006641,38.51802862706248,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2025-03-21,2.640000104904175,2.7200000286102295,2.4200000762939453,2.5399999618530273,297716,0.0,0.0,2.666000008583069,2.925,3.3439999997615812,-4.726183282985369,-8.854700561262598,-12.529904299983704,32.711217501780865,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2025-03-24,2.5,2.6600000858306885,2.5,2.559999942779541,161030,0.0,0.0,2.6420000076293944,2.9094999969005584,3.33599999944369,-3.1037117567395507,-9.19401923203737,-12.784772260619148,34.236480037226286,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2025-03-25,2.559999942779541,2.680000066757202,2.5399999618530273,2.559999942779541,134032,0.0,0.0,2.624000000953674,2.899499994516373,3.3273333330949146,-2.43902660635948,-9.5016380094407,-12.858144818950052,34.236480037226286,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2025-03-26,2.5799999237060547,2.6600000858306885,2.5399999618530273,2.5799999237060547,122193,0.0,0.0,2.6179999828338625,2.891999989748001,3.318499998251597,-1.451491954811799,-9.474412444172035,-12.852192518556699,35.921041055695056,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2025-03-27,2.5799999237060547,3.819999933242798,2.5399999618530273,2.7799999713897705,2175195,0.0,0.0,2.633999991416931,2.8909999907016752,3.3123333315054575,5.542899789240336,-8.889657561789468,-12.72013709478587,49.77582377898553,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2025-03-28,2.799999952316284,2.9000000953674316,2.0799999237060547,2.5999999046325684,1905630,0.0,0.0,2.6319999933242797,2.882999986410141,3.304333331187566,-1.21580884395423,-8.706208611481886,-12.750933472743784,41.151957385856896,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2025-03-31,2.5999999046325684,2.5999999046325684,2.380000114440918,2.440000057220459,374066,0.0,0.0,2.611999988555908,2.8729999899864196,3.2963333308696745,-6.5849897430720326,-9.084580659248283,-12.84255256951112,35.297818580822366,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2025-04-01,2.4149999618530273,2.549999952316284,2.2850000858306885,2.319999933242798,345267,0.0,0.0,2.5799999713897703,2.8614999890327453,3.287499996026357,-10.077520970161798,-9.837498470098845,-12.958175133339111,31.66008112798805,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2025-04-02,2.0999999046325684,2.1500000953674316,1.9600000381469727,1.9839999675750732,1243288,0.0,0.0,2.5043999671936037,2.836599987745285,3.2770333290100098,-20.77942846332503,-11.711204328663054,-13.440001887249014,24.15398003258241,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2025-04-03,1.9859999418258667,2.0350000858306885,1.840000033378601,1.8839999437332153,446829,0.0,0.0,2.424799954891205,2.8111999839544297,3.2647333294153214,-22.3028712148856,-13.745021032608559,-13.891895591426898,22.448176504429668,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2025-04-04,1.8960000276565552,2.0450000762939453,1.8380000591278076,1.8860000371932983,325205,0.0,0.0,2.3593999624252318,2.7853499829769133,3.2509499967098234,-20.064420309023177,-15.292513441935101,-14.321967861828949,22.565966134838746,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2025-04-07,1.8480000495910645,1.8600000143051147,1.5,1.850000023841858,451792,0.0,0.0,2.2883999705314637,2.7580999821424483,3.237199996908506,-19.157487866414836,-17.02983991342218,-14.799827481267558,21.920602359437737,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2025-04-08,1.8580000400543213,1.9119999408721924,1.8079999685287476,1.850000023841858,229612,0.0,0.0,2.2173999786376952,2.728349983692169,3.223283330599467,-16.5689527525637,-18.727436293309605,-15.354943892420708,21.920602359437737,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2025-04-09,1.8980000019073486,1.8980000019073486,1.659999966621399,1.8079999685287476,522726,0.0,0.0,2.1401999831199645,2.698549982905388,3.2090166638294857,-15.521914644020264,-20.69074144716331,-15.907261768934891,21.10396131845178,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2025-04-10,1.8200000524520874,1.8960000276565552,1.7960000038146973,1.8619999885559082,174830,0.0,0.0,2.0483999848365784,2.66909998357296,3.1945333311955135,-9.099785083992822,-23.255029881102047,-16.44789060397491,24.97403344451463,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2025-04-11,1.8700000047683716,1.8700000047683716,1.8179999589920044,1.8660000562667847,158939,0.0,0.0,1.975,2.6377499878406523,3.180583331982295,-5.518984492821033,-25.125580168543603,-17.06710019772764,25.266473892170524,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2025-04-14,1.850000023841858,1.9299999475479126,1.8480000495910645,1.9299999475479126,175743,0.0,0.0,1.9239999890327453,2.6054999858140944,3.1661666641632715,0.3118481574515856,-26.156208040370142,-17.70805955021782,29.969827323588603,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2025-04-15,1.9240000247955322,2.0,1.871999979019165,1.8980000019073486,217094,0.0,0.0,1.8817999958992004,2.5724499851465223,3.151649996638298,0.8608782040307729,-26.847946247164206,-18.377675570243472,28.98749701106594,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2025-04-16,1.9359999895095825,1.9359999895095825,1.8660000562667847,1.8960000276565552,122672,0.0,0.0,1.8730000019073487,2.537849986553192,3.137283331155777,1.227977881782415,-26.197371324883406,-19.106764717414077,28.923687295380873,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2025-04-17,1.899999976158142,1.940000057220459,1.8899999856948853,1.9320000410079956,92759,0.0,0.0,1.8778000116348266,2.5026499897241594,3.1230499972899755,2.88635792083003,-24.9675336405393,-19.865196141725804,31.832504124442778,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2025-04-22,1.9299999475479126,1.9320000410079956,1.8660000562667847,1.8700000047683716,270906,0.0,0.0,1.876200008392334,2.4668999910354614,3.1081333299477896,-0.33045536703067524,-23.945031610105357,-20.63081827069174,29.586747569161872,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2025-04-23,1.899999976158142,1.9079999923706055,1.8700000047683716,1.906000018119812,206338,0.0,0.0,1.8818000078201294,2.4370499938726424,3.0936833292245867,1.2860033052989446,-22.783692884780837,-21.224969251023033,32.56179094557673,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2025-04-24,1.906000018119812,1.9199999570846558,1.8359999656677246,1.8480000495910645,362806,0.0,0.0,1.88160001039505,2.4032499939203262,3.077749996383985,-1.785712192727464,-21.706022463120004,-21.915360352729152,30.33780121348653,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2025-04-25,1.8480000495910645,1.8839999437332153,1.8480000495910645,1.8819999694824219,56867,0.0,0.0,1.8890000104904174,2.369799992442131,3.0625999957323073,-0.37056860609430214,-20.28863125517351,-22.621302300515374,33.21734059728274,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2025-04-28,1.899999976158142,1.9500000476837158,1.8860000371932983,1.899999976158142,341461,0.0,0.0,1.892800009250641,2.3402999937534332,3.048099994659424,0.38038709173250673,-19.121479540966043,-23.221023002727176,34.75497366817926,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2025-04-29,1.9019999504089355,1.9320000410079956,1.8860000371932983,1.9299999475479126,154610,0.0,0.0,1.8991999983787538,2.3125499933958054,3.0338499933481216,1.621732792515329,-17.87420796080081,-23.775071329624243,37.34427513930703,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2025-04-30,1.9279999732971191,1.9880000352859497,1.9199999570846558,1.9859999418258667,222238,0.0,0.0,1.904799997806549,2.290199989080429,3.0197333256403605,4.262911807687027,-16.82822430842065,-24.158866293440916,41.97355066065513,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2025-05-02,1.99399995803833,2.0399999618530273,1.9900000095367432,2.015000104904175,162328,0.0,0.0,1.9165000081062318,2.2705749928951264,3.0061916589736937,5.139582383580306,-15.594066960872615,-24.470052129999754,44.26990648430231,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2025-05-05,2.0,2.0,1.9639999866485596,1.9980000257492065,126396,0.0,0.0,1.9267000079154968,2.2500249952077866,2.993174992998441,3.700628927222017,-14.369839800932132,-24.82815069379545,43.19085982760235,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2025-05-06,2.0,2.180000066757202,1.996000051498413,2.180000066757202,607668,0.0,0.0,1.9515000104904174,2.236524996161461,2.982674993077914,11.708944659926598,-12.744100162539246,-25.016134800073463,55.653189476852425,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2025-05-07,2.1700000762939453,2.200000047683716,1.9819999933242798,2.009999990463257,520108,0.0,0.0,1.965500009059906,2.2167749971151354,2.9702583263317743,2.264053991260733,-11.335159787629932,-25.367602626912923,45.592329299951466,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2025-05-08,2.059999942779541,2.059999942779541,1.8880000114440918,1.9279999732971191,382779,0.0,0.0,1.9677000045776367,2.194974997639656,2.957991658647855,-2.0175855663037985,-10.354331748945528,-25.79509170614045,41.67846074240503,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2025-05-09,1.9279999732971191,1.9279999732971191,1.8680000305175781,1.899999976158142,231444,0.0,0.0,1.9728999972343444,2.173974996805191,2.9431583245595294,-3.6950692472195854,-9.249186392039494,-26.134622841584765,40.40302932311248,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2025-05-12,1.9019999504089355,1.9019999504089355,1.6660000085830688,1.8660000562667847,598210,0.0,0.0,1.9713000059127808,2.1546249955892565,2.92754165828228,-5.3416501461044,-8.508440682335033,-26.401559837974375,38.848412694155634,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2025-05-13,1.850000023841858,1.944000005722046,1.7999999523162842,1.899999976158142,125335,0.0,0.0,1.9713000059127808,2.136624997854233,2.911208325624466,-3.6169040501587313,-7.737670021996583,-26.60693571642908,41.281560914462034,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2025-05-14,1.9140000343322754,1.9160000085830688,1.7680000066757202,1.8660000562667847,224507,0.0,0.0,1.964900016784668,2.1177750021219253,2.8924249937136968,-5.033332977406233,-7.218660395182807,-26.782025230571954,39.58534943679702,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2025-05-15,1.8660000562667847,1.8960000276565552,1.7999999523162842,1.805999994277954,148634,0.0,0.0,1.9469000220298767,2.0969249993562697,2.8748083263635635,-7.2371475760227995,-7.154522807084131,-27.0586153474539,36.71811775786069,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2025-05-16,1.8300000429153442,1.9240000247955322,1.8279999494552612,1.8600000143051147,196422,0.0,0.0,1.9314000129699707,2.0774249970912932,2.859308326244354,-3.696800154570882,-7.029133871296411,-27.345191212031665,40.86926810568206,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2025-05-19,1.8580000400543213,1.8580000400543213,1.7339999675750732,1.7879999876022339,541474,0.0,0.0,1.9104000091552735,2.0536249965429305,2.844041660428047,-6.407036273369868,-6.9742522431681415,-27.792021294306696,37.35110515199175,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2025-05-20,1.7879999876022339,1.7940000295639038,1.715999960899353,1.7860000133514404,235290,0.0,0.0,1.8710000038146972,2.0312749952077866,2.828091660141945,-4.543024601280286,-7.8903640211794315,-28.1750650505495,37.25516905202592,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2025-05-21,1.784000039100647,1.8279999494552612,1.7619999647140503,1.7979999780654907,116290,0.0,0.0,1.8498000025749206,2.012724995613098,2.812241659561793,-2.8003040565101243,-8.094746842876505,-28.429870570698977,38.279518543821354,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2025-05-22,1.7999999523162842,1.7999999523162842,1.718000054359436,1.75,140942,0.0,0.0,1.8320000052452088,1.9924749970436095,2.7958249926567076,-4.475982806246405,-8.054052976148258,-28.7339156679375,35.76435433100424,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2025-05-23,1.746000051498413,1.7979999780654907,1.722000002861023,1.7979999780654907,72648,0.0,0.0,1.8218000054359436,1.9734249979257583,2.779308326045672,-1.3064017619627606,-7.6833420398133105,-28.99582318981154,40.009266726760295,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2025-05-26,1.7999999523162842,1.812000036239624,1.7660000324249268,1.7879999876022339,78659,0.0,0.0,1.8139999985694886,1.953624999523163,2.762374993165334,-1.4332971878587741,-7.1469704261439,-29.277342708472947,39.42473955866104,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2025-05-27,1.7999999523162842,1.8200000524520874,1.7400000095367432,1.75600004196167,340822,0.0,0.0,1.7996000051498413,1.9280250012874602,2.745174994071325,-2.4227585609803937,-6.660961141679269,-29.76677241154534,37.53494650251269,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2025-05-28,1.7519999742507935,1.7660000324249268,1.7239999771118164,1.7640000581741333,63600,0.0,0.0,1.789400005340576,1.9071250051259994,2.728041661779086,-1.4194672566578213,-6.172904212833466,-30.09179325061069,38.33081250360942,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2025-05-30,1.7640000581741333,1.7640000581741333,1.6740000247955322,1.6979999542236328,222751,0.0,0.0,1.778600001335144,1.8885750025510788,2.710358328620593,-4.531656755369785,-5.823173613300033,-30.320098910602404,34.43303877979872,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2025-06-02,1.6979999542236328,1.8480000495910645,1.6679999828338623,1.7139999866485596,720394,0.0,0.0,1.7639999985694885,1.8734250038862228,2.6918083280324936,-2.834467798269634,-5.8409066330247335,-30.40273393999217,36.12868551912843,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2025-06-03,1.718000054359436,1.7300000190734863,1.6640000343322754,1.6979999542236328,329453,0.0,0.0,1.7549999952316284,1.866275003552437,2.6734583268562955,-3.2478655933256926,-5.962412190539848,-30.19247822923879,35.14974306958413,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2025-06-04,1.7000000476837158,1.7000000476837158,1.6619999408721924,1.687999963760376,102911,0.0,0.0,1.745199990272522,1.8613750040531158,2.6551916589339575,-3.2775628484397292,-6.241354564643051,-29.89677420120979,34.52017684786692,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2025-06-05,1.6720000505447388,1.6779999732971191,1.5800000429153442,1.5800000429153442,684575,0.0,0.0,1.7233999967575073,1.853725004196167,2.6370249927043914,-8.320758623184581,-7.030439096610919,-29.70392736797363,28.568773392660034,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2025-06-09,1.5980000495910645,1.7680000066757202,1.5540000200271606,1.718000054359436,1314453,0.0,0.0,1.720200002193451,1.8504250049591064,2.620341659585635,-0.12788907285255835,-7.037572580172383,-29.382300274090152,42.265636918770845,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2025-06-10,1.7039999961853027,1.718000054359436,1.6360000371932983,1.6360000371932983,295785,0.0,0.0,1.7040000081062316,1.8450750052928924,2.602474993467331,-3.9906086026669794,-7.646030474748428,-29.10306496990924,37.64634562297373,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2025-06-11,1.6460000276565552,1.6460000276565552,1.6160000562667847,1.6180000305175781,101693,0.0,0.0,1.6870000123977662,1.8403250068426131,2.584458327293396,-4.090099666455666,-8.33140852157966,-28.792622136418238,36.69819775044924,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2025-06-12,1.6460000276565552,1.746000051498413,1.6460000276565552,1.7039999961853027,1027134,0.0,0.0,1.6818000078201294,1.836375007033348,2.5681583265463512,1.320013572478688,-8.417398332105027,-28.494478395228164,43.96025539998396,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2025-06-13,1.7139999866485596,1.8200000524520874,1.659999966621399,1.7799999713897705,1741655,0.0,0.0,1.683399999141693,1.8342250049114228,2.5531583269437155,5.738384952912584,-8.22281919425765,-28.15858752061409,49.47642426881334,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2025-06-16,1.7519999742507935,1.7519999742507935,1.6480000019073486,1.7000000476837158,887199,0.0,0.0,1.6836000084877014,1.8284750074148177,2.5381583273410797,0.9741054355746759,-7.923269300352498,-27.96056149380212,44.50983551723192,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2025-06-17,1.6979999542236328,1.6979999542236328,1.5540000200271606,1.6299999952316284,1699759,0.0,0.0,1.6752000093460082,1.8217750072479248,2.5225749939680098,-2.698186118804149,-8.045724489509878,-27.781135878847618,40.66341129563439,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2025-06-18,1.6640000343322754,1.7100000381469727,1.6139999628067017,1.7079999446868896,804230,0.0,0.0,1.676200008392334,1.8170750051736833,2.507641660173734,1.8971445015714634,-7.752844344908249,-27.53849028621605,46.238516589734616,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2025-06-19,1.753999948501587,1.8980000019073486,1.7200000286102295,1.7979999780654907,2500712,0.0,0.0,1.6872000098228455,1.8137250036001205,2.493458326657613,6.567091488713253,-6.975974501433872,-27.26066506868994,51.859057583449676,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2025-06-23,1.899999976158142,1.899999976158142,1.6779999732971191,1.7000000476837158,1710517,0.0,0.0,1.6992000102996827,1.8094750046730042,2.4786249935626983,0.0470831790950857,-6.094308796116782,-26.996822457110735,46.19567415550654,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2025-06-24,1.7079999446868896,1.7079999446868896,1.5880000591278076,1.6419999599456787,860522,0.0,0.0,1.691600000858307,1.802875003218651,2.463141659895579,-2.9321376736498888,-6.17208637102883,-26.805874279472786,43.18948089816824,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2025-06-25,1.6380000114440918,1.649999976158142,1.6080000400543213,1.6239999532699585,649808,0.0,0.0,1.690399992465973,1.797275000810623,2.4491749932368596,-3.9280666997134435,-5.946502805438589,-26.617125939403678,42.2701371170561,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2025-06-26,1.628000020980835,1.628000020980835,1.5399999618530273,1.5759999752044678,908785,0.0,0.0,1.6861999869346618,1.7896250009536743,2.434641660253207,-6.535405799078808,-5.779144455620495,-26.493289334104702,39.83502950798928,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
2025-06-27,1.5800000429153442,1.649999976158142,1.5779999494552612,1.600000023841858,1013421,0.0,0.0,1.6757999897003173,1.7821250021457673,2.4191416601339975,-4.523210784361842,-5.966192737177773,-26.332342106536476,41.64518937296898,,1.136,-1.06059,1.0,-0.18739,0.677,1.2084593,-2.6666665,Alzinova AB (publ),Healthcare,"Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden."
